windz123的个人主页 - 老虎社区

windz123

windz123

暂无个人介绍

IP属地：未知

260关注

2粉丝

0主题

0勋章

2021-12-23

ok

France cancels order for Merck's COVID-19 antiviral drug

2021-12-23

m

抱歉，原内容已删除

2021-12-23

.

Biogen shares fell 1.2% in early trading

2021-12-23

ok

抱歉，原内容已删除

2021-12-23

ok

抱歉，原内容已删除

2021-12-23

ok

Philips receives FDA De Novo Clearance for IVC Filter Removal Laser Sheath - CavaClear - with Breakthrough Device Designation

2021-12-23

ok

Apple iPhone production may surprise to upside, Morgan Stanley says

2021-12-19

dkejeueu

2021-12-08

ok

抱歉，原内容已删除

2021-11-20

ok

U.S. vehicle fuel economy hits new high in 2020 -- EPA

2021-11-18

ok

Record selling by insiders is setting up stocks for a big fall, says contrarian investor

2021-11-10

ok

抱歉，原内容已删除

2021-11-08

ok

抱歉，原内容已删除

2021-11-03

ok

抱歉，原内容已删除

2021-11-01

Great ariticle, would you like to share it?

@小虎活动:[Halloween Game] Trade or Treat!

2021-10-29

Great ariticle, would you like to share it?

@小虎活动:[Halloween Game] Trade or Treat!

2021-10-15

ok

Software development platform Gitlab spikes 23% on its first day of trading

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":3580791049174344,"uuid":"3580791049174344","gmtCreate":1617697026770,"gmtModify":1618714276061,"name":"windz123","pinyin":"windz123","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/3f5527e97f3d63e3fa0d4f05b7f5230c","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":2,"headSize":260,"tweetSize":73,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":2,"name":"无畏虎","nameTw":"無畏虎","represent":"初生牛犊","factor":"发布3条非转发主帖,1条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"35ec162348d5460f88c959321e554969-2","templateUuid":"35ec162348d5460f88c959321e554969","name":"宗师交易员","description":"证券或期货账户累计交易次数达到100次","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.05.10","exceedPercentage":"80.94%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"228c86a078844d74991fff2b7ab2428d-2","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资总监虎","description":"证券账户累计交易金额达到30万美元","bigImgUrl":"https://static.tigerbbs.com/9d20b23f1b6335407f882bc5c2ad12c0","smallImgUrl":"https://static.tigerbbs.com/ada3b4533518ace8404a3f6dd192bd29","grayImgUrl":"https://static.tigerbbs.com/177f283ba21d1c077054dac07f88f3bd","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"80.86%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.08.23","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":3,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":691210367,"gmtCreate":1640193824058,"gmtModify":1640193824123,"author":{"id":"3580791049174344","authorId":"3580791049174344","name":"windz123","avatar":"https://static.tigerbbs.com/3f5527e97f3d63e3fa0d4f05b7f5230c","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"ok","listText":"ok","text":"ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/691210367","repostId":"2193019234","repostType":4,"repost":{"id":"2193019234","pubTimestamp":1640181878,"share":"https://www.laohu8.com/m/news/2193019234?lang=&edition=full","pubTime":"2021-12-22 22:04","market":"us","language":"en","title":"France cancels order for Merck's COVID-19 antiviral drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2193019234","media":"Reuters","summary":"PARIS, Dec 22 (Reuters) - France has cancelled its order for Merck & Co's COVID-19 antiviral drug fo","content":"<p>PARIS, Dec 22 (Reuters) - France has cancelled its order for Merck &amp; Co's COVID-19 antiviral drug following disappointing trial data and hopes instead to receive Pfizer's competing drug before the end of January, the health minister said on Wednesday.</p>\n<p>France is the first country to publicly say it has cancelled an order for the Merck treatment after the company released data in late November suggesting its drug was markedly less effective than previously thought, reducing hospitalisations and deaths in its clinical trial of high-risk individuals by about 30%.</p>\n<p>\"The latest studies weren't good,\" Olivier Veran told BFM TV.</p>\n<p>Merck did not immediately respond to Reuters' request for comment.</p>\n<p>While vaccines are the main weapons against COVID-19 for governments, there are hopes Merck and Pfizer's experimental pills could be a game-changer in reducing the chances of dying or hospitalisation for those most at risk of severe illness.</p>\n<p>France had placed an early order for 50,000 doses of the drug molnupiravir developed by Merck and Ridgeback Biotherapeutics.</p>\n<p>The cancellation would not incur a cost, Veran said.</p>\n<p>In Italy, the office of the special commissioner for the COVID emergency said on Nov 18 it had received a mandate from the health ministry to buy 50,000 courses of Merck's pill and another 50,000 of Pfizer's <a href=\"https://laohu8.com/S/AONE.U\">one</a>. \"The contract has not yet been finalised, but is in progress,\" a spokesperson for the commissioner told Reuters on Tuesday.</p>\n<p>Italian drug regulator Aifa's head Nicola Magrini told a Senate committee on Dec. 9 the two treatments could be available in Italy from the end of January.</p>\n<p>However, regardless of the availability of the drugs, there will be assessments of their use, two top government scientific advisers told Reuters.</p>\n<p>\"There must and will be an evaluation, independently of the assessments of regulatory bodies,\" Walter Ricciardi, top adviser of health minister Roberto Speranza, told Reuters.</p>\n<p>Germany has already bought Merck's antiviral treatment, health minister Karl Lauterbach told Reuters on Wednesday.</p>\n<p>\"This is a binding order,\" he said, adding Berlin was also in talks with Pfizer about buying its antiviral drug.</p>\n<p>The European Medicines Agency is expected to decide whether to approve the Merck and Pfizer pills in the new year.</p>\n<p>Pfizer's Paxlovid has shown near 90% efficacy in preventing COVID-19 hospitalisations and deaths in high-risk patients.</p>\n<p>France had purchased that drug instead, Veran said, without saying how many doses it had secured.</p>\n<p>\"France is lined up to get it before the end of January,\" Veran continued. It has not yet been decided whether the drug would be available over the counter in pharmacies, the minister said.</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>France cancels order for Merck's COVID-19 antiviral drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFrance cancels order for Merck's COVID-19 antiviral drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-22 22:04 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/1-france-cancels-order-mercks-135238223.html><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>PARIS, Dec 22 (Reuters) - France has cancelled its order for Merck & Co's COVID-19 antiviral drug following disappointing trial data and hopes instead to receive Pfizer's competing drug before the end...</p>\n\n<a href=\"https://finance.yahoo.com/news/1-france-cancels-order-mercks-135238223.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4568":"美国抗疫概念","BK4516":"特朗普概念","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4550":"红杉资本持仓","BK4007":"制药","PFE":"辉瑞","MRK":"默沙东","BK4534":"瑞士信贷持仓","BK4559":"巴菲特持仓"},"source_url":"https://finance.yahoo.com/news/1-france-cancels-order-mercks-135238223.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2193019234","content_text":"PARIS, Dec 22 (Reuters) - France has cancelled its order for Merck & Co's COVID-19 antiviral drug following disappointing trial data and hopes instead to receive Pfizer's competing drug before the end of January, the health minister said on Wednesday.\nFrance is the first country to publicly say it has cancelled an order for the Merck treatment after the company released data in late November suggesting its drug was markedly less effective than previously thought, reducing hospitalisations and deaths in its clinical trial of high-risk individuals by about 30%.\n\"The latest studies weren't good,\" Olivier Veran told BFM TV.\nMerck did not immediately respond to Reuters' request for comment.\nWhile vaccines are the main weapons against COVID-19 for governments, there are hopes Merck and Pfizer's experimental pills could be a game-changer in reducing the chances of dying or hospitalisation for those most at risk of severe illness.\nFrance had placed an early order for 50,000 doses of the drug molnupiravir developed by Merck and Ridgeback Biotherapeutics.\nThe cancellation would not incur a cost, Veran said.\nIn Italy, the office of the special commissioner for the COVID emergency said on Nov 18 it had received a mandate from the health ministry to buy 50,000 courses of Merck's pill and another 50,000 of Pfizer's one. \"The contract has not yet been finalised, but is in progress,\" a spokesperson for the commissioner told Reuters on Tuesday.\nItalian drug regulator Aifa's head Nicola Magrini told a Senate committee on Dec. 9 the two treatments could be available in Italy from the end of January.\nHowever, regardless of the availability of the drugs, there will be assessments of their use, two top government scientific advisers told Reuters.\n\"There must and will be an evaluation, independently of the assessments of regulatory bodies,\" Walter Ricciardi, top adviser of health minister Roberto Speranza, told Reuters.\nGermany has already bought Merck's antiviral treatment, health minister Karl Lauterbach told Reuters on Wednesday.\n\"This is a binding order,\" he said, adding Berlin was also in talks with Pfizer about buying its antiviral drug.\nThe European Medicines Agency is expected to decide whether to approve the Merck and Pfizer pills in the new year.\nPfizer's Paxlovid has shown near 90% efficacy in preventing COVID-19 hospitalisations and deaths in high-risk patients.\nFrance had purchased that drug instead, Veran said, without saying how many doses it had secured.\n\"France is lined up to get it before the end of January,\" Veran continued. It has not yet been decided whether the drug would be available over the counter in pharmacies, the minister said.","news_type":1},"isVote":1,"tweetType":1,"viewCount":597,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691210098,"gmtCreate":1640193809019,"gmtModify":1640193809090,"author":{"id":"3580791049174344","authorId":"3580791049174344","name":"windz123","avatar":"https://static.tigerbbs.com/3f5527e97f3d63e3fa0d4f05b7f5230c","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"m","listText":"m","text":"m","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/691210098","repostId":"1118823516","repostType":4,"isVote":1,"tweetType":1,"viewCount":409,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691237716,"gmtCreate":1640193800525,"gmtModify":1640193800625,"author":{"id":"3580791049174344","authorId":"3580791049174344","name":"windz123","avatar":"https://static.tigerbbs.com/3f5527e97f3d63e3fa0d4f05b7f5230c","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":".","listText":".","text":".","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/691237716","repostId":"1104039472","repostType":4,"repost":{"id":"1104039472","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1640184691,"share":"https://www.laohu8.com/m/news/1104039472?lang=&edition=full","pubTime":"2021-12-22 22:51","market":"us","language":"en","title":"Biogen shares fell 1.2% in early trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1104039472","media":"Tiger Newspress","summary":"Biogen shares fell 1.2% in early trading.A Japanese health ministry panel said on Wednesday that inc","content":"<p>Biogen&nbsp;shares&nbsp;fell&nbsp;1.2%&nbsp;in&nbsp;early&nbsp;trading.<img src=\"https://static.tigerbbs.com/22ab29bf4110d582a44955c778f3cf48\" tg-width=\"713\" tg-height=\"596\" width=\"100%\" height=\"auto\">A Japanese health ministry panel said on Wednesday that inconsistent trial results made it difficult to determine the efficacy of an Alzheimer's treatment developed by Eisai Co and Biogen Inc.</p>\n<p>Tokyo-based Eisai and its United States partner filed for Japanese regulatory approval just over a year ago for the drug Aduhelm, which was approved in the United States in June.</p>\n<p>In a statement the panel cited inconsistent results from global Phase III trials and a lack of clinical significance in the drug's ability to reduce plaques in the brain. The panel said it would take another look if further data is submitted.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biogen shares fell 1.2% in early trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiogen shares fell 1.2% in early trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-22 22:51</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Biogen&nbsp;shares&nbsp;fell&nbsp;1.2%&nbsp;in&nbsp;early&nbsp;trading.<img src=\"https://static.tigerbbs.com/22ab29bf4110d582a44955c778f3cf48\" tg-width=\"713\" tg-height=\"596\" width=\"100%\" height=\"auto\">A Japanese health ministry panel said on Wednesday that inconsistent trial results made it difficult to determine the efficacy of an Alzheimer's treatment developed by Eisai Co and Biogen Inc.</p>\n<p>Tokyo-based Eisai and its United States partner filed for Japanese regulatory approval just over a year ago for the drug Aduhelm, which was approved in the United States in June.</p>\n<p>In a statement the panel cited inconsistent results from global Phase III trials and a lack of clinical significance in the drug's ability to reduce plaques in the brain. The panel said it would take another look if further data is submitted.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BIIB":"渤健公司"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1104039472","content_text":"Biogen shares fell 1.2% in early trading.A Japanese health ministry panel said on Wednesday that inconsistent trial results made it difficult to determine the efficacy of an Alzheimer's treatment developed by Eisai Co and Biogen Inc.\nTokyo-based Eisai and its United States partner filed for Japanese regulatory approval just over a year ago for the drug Aduhelm, which was approved in the United States in June.\nIn a statement the panel cited inconsistent results from global Phase III trials and a lack of clinical significance in the drug's ability to reduce plaques in the brain. The panel said it would take another look if further data is submitted.","news_type":1},"isVote":1,"tweetType":1,"viewCount":379,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691237334,"gmtCreate":1640193698047,"gmtModify":1640193698145,"author":{"id":"3580791049174344","authorId":"3580791049174344","name":"windz123","avatar":"https://static.tigerbbs.com/3f5527e97f3d63e3fa0d4f05b7f5230c","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"ok","listText":"ok","text":"ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/691237334","repostId":"1101599012","repostType":4,"isVote":1,"tweetType":1,"viewCount":506,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691237022,"gmtCreate":1640193637456,"gmtModify":1640193637522,"author":{"id":"3580791049174344","authorId":"3580791049174344","name":"windz123","avatar":"https://static.tigerbbs.com/3f5527e97f3d63e3fa0d4f05b7f5230c","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"ok","listText":"ok","text":"ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/691237022","repostId":"1118823516","repostType":4,"isVote":1,"tweetType":1,"viewCount":358,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691234756,"gmtCreate":1640193600570,"gmtModify":1640193600641,"author":{"id":"3580791049174344","authorId":"3580791049174344","name":"windz123","avatar":"https://static.tigerbbs.com/3f5527e97f3d63e3fa0d4f05b7f5230c","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"ok","listText":"ok","text":"ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/691234756","repostId":"2193927561","repostType":4,"repost":{"id":"2193927561","pubTimestamp":1640184600,"share":"https://www.laohu8.com/m/news/2193927561?lang=&edition=full","pubTime":"2021-12-22 22:50","market":"us","language":"en","title":"Philips receives FDA De Novo Clearance for IVC Filter Removal Laser Sheath - CavaClear - with Breakthrough Device Designation","url":"https://stock-news.laohu8.com/highlight/detail?id=2193927561","media":"GlobeNewswire","summary":"Philips IVC Filter Removal Laser Sheath – CavaClear – is intended to safely ablate tissue to remove ","content":"<ul>\n <li><i>Philips IVC Filter Removal Laser Sheath – CavaClear – is intended to safely ablate tissue to remove embedded IVC filters</i></li>\n <li><i>CavaClear is a first-in-class FDA-cleared solution for advanced IVC filter removal</i></li>\n <li><i>It is estimated that in the United States more than <a href=\"https://laohu8.com/S/AONE.U\">one</a> million patients with IVC filters would benefit from filter removal to reduce the risk of long-term complications [1,2]</i></li>\n <li><i><a href=\"https://laohu8.com/S/TWOA.U\">Two</a> independent and prospective clinical studies demonstrated that laser-assisted retrieval was 96-99.4% effective with a major adverse event rate of 0.7-2% [3,4]</i></li>\n</ul>\n<p><b>Amsterdam, the Netherlands –</b> <u>Royal Philips</u> (NYSE: PHG, AEX: PHIA), a global leader in health technology today announced the FDA has granted De Novo Clearance for Philips IVC Filter Removal Laser Sheath – CavaClear – to remove an IVC filter when previous methods of removal have failed. CavaClear is the first and only FDA-cleared solution for advanced IVC filter removal. Earlier in 2021, the FDA granted the device <u>Breakthrough Device Designation</u>. Laser has been clinically proven to provide a success rate over 99%, with low complication rates [3].</p>\n<p>IVC filters are used to treat patients with venous thromboembolism, in which blood clots form in the deep veins of the leg and groin, and can travel through the circulatory system. They are placed in the inferior vena cava to capture blood clots from moving to the lungs. However, research has shown that IVC filters may have long-term complications [5]. The filters can fracture and travel through the bloodstream to other parts of the body. Other identified long-term risks associated with IVC filters include lower limb deep vein thrombosis and IVC occlusion. The FDA recommends that implanting physicians consider removing retrievable IVC filters as soon as they are no longer indicated [2].</p>\n<p>Failure rates for IVC filter removal can be high and prior to CavaClear, limited options for removal existed if the filter became difficult to remove. Advanced retrieval tools and techniques are required if the IVC filter becomes embedded in the vasculature. Physicians previously had very few tools to remove the filter when complications occurred and until now there were no FDA-approved devices for this type of advanced removal.</p>\n<p>“Today is a historic day. With the approval of CavaClear, physicians now have a device specifically geared remove chronically embedded IVC filters,” said Kush R. Desai MD, FSIR, Associate Professor of Radiology, Surgery, and Medicine, and Director of Deep Venous Interventions at Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA. “Backed by evidence, this technology can be applied to retrieve IVC filters that are no longer indicated, reducing potential clinical risk for patients and satisfying the FDA’s guidance to retrieve filters when they are no longer indicated.”</p>\n<p><b>Clinical research supports laser-assisted removal</b></p>\n<p><a href=\"https://laohu8.com/S/TWOA\">Two</a> independent and prospective clinical studies demonstrated that laser-assisted retrieval was 96-99.4% effective with a major adverse event rate of 0.7-2% [3,4]. Philips CavaClear uses circumferential tissue ablation that can aid in capturing the filter within seconds of laser activation, which can help increase physician efficiency during removal, and may help lower costs by reducing the number of retrieval attempts needed to remove an embedded filter. In addition, the simple and safe design is easy for physicians to integrate into their workflow.</p>\n<p>“With the FDA’s clearance of our IVC Filter Removal Laser Sheath – CavaClear – more than one million patients and their physicians now have access to a safe, effective and efficient option for advanced IVC filter removal,” said Chris Landon, Senior Vice President and General Manager Image Guided Therapy Devices at Philips. “This clearance demonstrates the commitment of Philips to innovating procedures with physician collaboration to meet unmet needs that can have a critical impact on the lives of patients and their families.”</p>\n<p>[1] Philips internal market research data calculation.</p>\n<p>[2] <u>Health, C. for D. and R. Safety Communications - Removing Retrievable Inferior Vena Cava Filters: FDA Safety Communication. (2014)</u>.</p>\n<p>[3] Kuo, W. et al. Laser‐Assisted Removal of Embedded Vena Cava Filters: A First‐In‐Human Escalation Trial in 500 Patients Refractory to High‐Force Retrieval.&nbsp;Journal of the American Heart Association&nbsp;9:24, 1-9 (2020).</p>\n<p>[4] Desai, K. et al. Excimer Laser Sheath-Assisted Retrieval of “Closed-Cell” Design Inferior Vena Cava Filters. J Am Heart Assoc; 9: e017240 (2020).</p>\n<p>[5] Van Ha, T. G. Complications of inferior vena caval filters. <i>Semin. Interv. Radiol.</i> 23, 150–155 (2006).</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Philips receives FDA De Novo Clearance for IVC Filter Removal Laser Sheath - CavaClear - with Breakthrough Device Designation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPhilips receives FDA De Novo Clearance for IVC Filter Removal Laser Sheath - CavaClear - with Breakthrough Device Designation\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-22 22:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/philips-receives-fda-novo-clearance-140000021.html><strong>GlobeNewswire</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Philips IVC Filter Removal Laser Sheath – CavaClear – is intended to safely ablate tissue to remove embedded IVC filters\nCavaClear is a first-in-class FDA-cleared solution for advanced IVC filter ...</p>\n\n<a href=\"https://finance.yahoo.com/news/philips-receives-fda-novo-clearance-140000021.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PHG":"飞利浦","BK4082":"医疗保健设备"},"source_url":"https://finance.yahoo.com/news/philips-receives-fda-novo-clearance-140000021.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2193927561","content_text":"Philips IVC Filter Removal Laser Sheath – CavaClear – is intended to safely ablate tissue to remove embedded IVC filters\nCavaClear is a first-in-class FDA-cleared solution for advanced IVC filter removal\nIt is estimated that in the United States more than one million patients with IVC filters would benefit from filter removal to reduce the risk of long-term complications [1,2]\nTwo independent and prospective clinical studies demonstrated that laser-assisted retrieval was 96-99.4% effective with a major adverse event rate of 0.7-2% [3,4]\n\nAmsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology today announced the FDA has granted De Novo Clearance for Philips IVC Filter Removal Laser Sheath – CavaClear – to remove an IVC filter when previous methods of removal have failed. CavaClear is the first and only FDA-cleared solution for advanced IVC filter removal. Earlier in 2021, the FDA granted the device Breakthrough Device Designation. Laser has been clinically proven to provide a success rate over 99%, with low complication rates [3].\nIVC filters are used to treat patients with venous thromboembolism, in which blood clots form in the deep veins of the leg and groin, and can travel through the circulatory system. They are placed in the inferior vena cava to capture blood clots from moving to the lungs. However, research has shown that IVC filters may have long-term complications [5]. The filters can fracture and travel through the bloodstream to other parts of the body. Other identified long-term risks associated with IVC filters include lower limb deep vein thrombosis and IVC occlusion. The FDA recommends that implanting physicians consider removing retrievable IVC filters as soon as they are no longer indicated [2].\nFailure rates for IVC filter removal can be high and prior to CavaClear, limited options for removal existed if the filter became difficult to remove. Advanced retrieval tools and techniques are required if the IVC filter becomes embedded in the vasculature. Physicians previously had very few tools to remove the filter when complications occurred and until now there were no FDA-approved devices for this type of advanced removal.\n“Today is a historic day. With the approval of CavaClear, physicians now have a device specifically geared remove chronically embedded IVC filters,” said Kush R. Desai MD, FSIR, Associate Professor of Radiology, Surgery, and Medicine, and Director of Deep Venous Interventions at Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA. “Backed by evidence, this technology can be applied to retrieve IVC filters that are no longer indicated, reducing potential clinical risk for patients and satisfying the FDA’s guidance to retrieve filters when they are no longer indicated.”\nClinical research supports laser-assisted removal\nTwo independent and prospective clinical studies demonstrated that laser-assisted retrieval was 96-99.4% effective with a major adverse event rate of 0.7-2% [3,4]. Philips CavaClear uses circumferential tissue ablation that can aid in capturing the filter within seconds of laser activation, which can help increase physician efficiency during removal, and may help lower costs by reducing the number of retrieval attempts needed to remove an embedded filter. In addition, the simple and safe design is easy for physicians to integrate into their workflow.\n“With the FDA’s clearance of our IVC Filter Removal Laser Sheath – CavaClear – more than one million patients and their physicians now have access to a safe, effective and efficient option for advanced IVC filter removal,” said Chris Landon, Senior Vice President and General Manager Image Guided Therapy Devices at Philips. “This clearance demonstrates the commitment of Philips to innovating procedures with physician collaboration to meet unmet needs that can have a critical impact on the lives of patients and their families.”\n[1] Philips internal market research data calculation.\n[2] Health, C. for D. and R. Safety Communications - Removing Retrievable Inferior Vena Cava Filters: FDA Safety Communication. (2014).\n[3] Kuo, W. et al. Laser‐Assisted Removal of Embedded Vena Cava Filters: A First‐In‐Human Escalation Trial in 500 Patients Refractory to High‐Force Retrieval. Journal of the American Heart Association 9:24, 1-9 (2020).\n[4] Desai, K. et al. Excimer Laser Sheath-Assisted Retrieval of “Closed-Cell” Design Inferior Vena Cava Filters. J Am Heart Assoc; 9: e017240 (2020).\n[5] Van Ha, T. G. Complications of inferior vena caval filters. Semin. Interv. Radiol. 23, 150–155 (2006).","news_type":1},"isVote":1,"tweetType":1,"viewCount":448,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691234475,"gmtCreate":1640193526397,"gmtModify":1640193526509,"author":{"id":"3580791049174344","authorId":"3580791049174344","name":"windz123","avatar":"https://static.tigerbbs.com/3f5527e97f3d63e3fa0d4f05b7f5230c","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"ok","listText":"ok","text":"ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/691234475","repostId":"1122126959","repostType":4,"repost":{"id":"1122126959","pubTimestamp":1640186098,"share":"https://www.laohu8.com/m/news/1122126959?lang=&edition=full","pubTime":"2021-12-22 23:14","market":"us","language":"en","title":"Apple iPhone production may surprise to upside, Morgan Stanley says","url":"https://stock-news.laohu8.com/highlight/detail?id=1122126959","media":"seekingalpha","summary":"Apple(NASDAQ:AAPL)iPhone production could surprise to the upside this quarter, Morgan Stanley analys","content":"<p>Apple(NASDAQ:AAPL)iPhone production could surprise to the upside this quarter, Morgan Stanley analyst Katy Huberty wrote in a note to clients, as lead times are declining to \"more normalized levels.\"</p>\n<p>Citing a \"handful\" of data points that the firm has seen over the past month, Huberty notes that the supply of semi-related components are improving and iPhone builds in the December quarter are \"stable\" at 82 million units. In addition, Apple (AAPL) is seeing improved supply for power management integrated circuits and world-facing camera modules, all of which suggests that iPhone builds in December are likely to be flat or slightly down month-over-month, compared to a significant month-over-month decline in previous years.</p>\n<p>Additionally, Huberty notes that lead times for Apple's (AAPL) high-end iPhone 13 models, the Pro and Pro Max are at 2 days as of December 21, down from 20 days a month ago.</p>\n<p>'[W]hile some investors may view this lead time contraction as a sign of slowing demand, we'd note that major end markets like China are posting iPhone shipment growth of +46% [year-over-year] [quarter-to-date] through the end of November,\" Huberty wrote.</p>\n<p>\"While we don't have enough data to definitively say that iPhone will exit the December quarter in supply/demand balance, we do believe that iPhone production is surprising to the upside, which supports our 7% above consensus December quarter iPhone revenue forecast.\"</p>\n<p>Apple (AAPL) shares have&nbsp;gained more than 33% year-to-date.</p>\n<p>Huberty added that she is keeping an eye on Apple (AAPL) retail stores that are closing as a result of increasing COVID-19 cases in North America.</p>\n<p>On Tuesday, Apple (AAPL) was upgraded at Moody's, as the credit-ratings agency&nbsp;cited the tech giant's \"exceptional liquidity\" and earnings power.</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Apple iPhone production may surprise to upside, Morgan Stanley says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nApple iPhone production may surprise to upside, Morgan Stanley says\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-22 23:14 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3782708-apple-iphone-production-may-surprise-to-upside-morgan-stanley-says><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Apple(NASDAQ:AAPL)iPhone production could surprise to the upside this quarter, Morgan Stanley analyst Katy Huberty wrote in a note to clients, as lead times are declining to \"more normalized levels.\"\n...</p>\n\n<a href=\"https://seekingalpha.com/news/3782708-apple-iphone-production-may-surprise-to-upside-morgan-stanley-says\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AAPL":"苹果"},"source_url":"https://seekingalpha.com/news/3782708-apple-iphone-production-may-surprise-to-upside-morgan-stanley-says","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1122126959","content_text":"Apple(NASDAQ:AAPL)iPhone production could surprise to the upside this quarter, Morgan Stanley analyst Katy Huberty wrote in a note to clients, as lead times are declining to \"more normalized levels.\"\nCiting a \"handful\" of data points that the firm has seen over the past month, Huberty notes that the supply of semi-related components are improving and iPhone builds in the December quarter are \"stable\" at 82 million units. In addition, Apple (AAPL) is seeing improved supply for power management integrated circuits and world-facing camera modules, all of which suggests that iPhone builds in December are likely to be flat or slightly down month-over-month, compared to a significant month-over-month decline in previous years.\nAdditionally, Huberty notes that lead times for Apple's (AAPL) high-end iPhone 13 models, the Pro and Pro Max are at 2 days as of December 21, down from 20 days a month ago.\n'[W]hile some investors may view this lead time contraction as a sign of slowing demand, we'd note that major end markets like China are posting iPhone shipment growth of +46% [year-over-year] [quarter-to-date] through the end of November,\" Huberty wrote.\n\"While we don't have enough data to definitively say that iPhone will exit the December quarter in supply/demand balance, we do believe that iPhone production is surprising to the upside, which supports our 7% above consensus December quarter iPhone revenue forecast.\"\nApple (AAPL) shares have gained more than 33% year-to-date.\nHuberty added that she is keeping an eye on Apple (AAPL) retail stores that are closing as a result of increasing COVID-19 cases in North America.\nOn Tuesday, Apple (AAPL) was upgraded at Moody's, as the credit-ratings agency cited the tech giant's \"exceptional liquidity\" and earnings power.","news_type":1},"isVote":1,"tweetType":1,"viewCount":716,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":699550744,"gmtCreate":1639846437194,"gmtModify":1639846437302,"author":{"id":"3580791049174344","authorId":"3580791049174344","name":"windz123","avatar":"https://static.tigerbbs.com/3f5527e97f3d63e3fa0d4f05b7f5230c","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"dkejeueu","listText":"dkejeueu","text":"dkejeueu","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/699550744","isVote":1,"tweetType":1,"viewCount":548,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":602194376,"gmtCreate":1638978900994,"gmtModify":1638978901060,"author":{"id":"3580791049174344","authorId":"3580791049174344","name":"windz123","avatar":"https://static.tigerbbs.com/3f5527e97f3d63e3fa0d4f05b7f5230c","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"ok","listText":"ok","text":"ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/602194376","repostId":"1147964036","repostType":4,"isVote":1,"tweetType":1,"viewCount":596,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":876486944,"gmtCreate":1637339698991,"gmtModify":1637339699112,"author":{"id":"3580791049174344","authorId":"3580791049174344","name":"windz123","avatar":"https://static.tigerbbs.com/3f5527e97f3d63e3fa0d4f05b7f5230c","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"ok","listText":"ok","text":"ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/876486944","repostId":"1197931355","repostType":4,"repost":{"id":"1197931355","pubTimestamp":1637334995,"share":"https://www.laohu8.com/m/news/1197931355?lang=&edition=full","pubTime":"2021-11-19 23:16","market":"us","language":"en","title":"U.S. vehicle fuel economy hits new high in 2020 -- EPA","url":"https://stock-news.laohu8.com/highlight/detail?id=1197931355","media":"Reuters","summary":"The U.S. Environmental Protection Agency said the fuel economy for new vehicles hit a new high in th","content":"<p>The U.S. Environmental Protection Agency said the fuel economy for new vehicles hit a new high in the 2020 model year at 25.4 miles per gallon but most automakers relied on credits to meet federal emissions requirements.</p>\n<p>The report said since 2004, carbon dioxide emissions have decreased by 24% as fuel economy has improved by 32%.</p>\n<p>The report said only Tesla Inc, Subaru&nbsp;and Honda&nbsp;met requirements without using credits. Automakers can either purchase credits or use credits earned from earlier model years.</p>\n<p>Detroit's Big Three automakers -- General Motors&nbsp;, Ford Motor Co&nbsp;and Chrysler parent Stellantis -- had the lowest average fleetwide fuel economy in 2020 in part because they sell more large trucks and sport utility vehicles than other automakers.</p>\n<p>GM and Ford both averaged 23 miles per gallon, while Stellantis averaged 21.8 mpg. Tesla, which only makes electric vehicles, led the industry, while Honda averaged 29.1 mpg, which was first among automakers building gas-powered vehicles.</p>","source":"lsy1601381805984","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>U.S. vehicle fuel economy hits new high in 2020 -- EPA</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nU.S. vehicle fuel economy hits new high in 2020 -- EPA\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-19 23:16 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.reuters.com/business/autos-transportation/us-vehicle-fuel-economy-hits-new-high-2020-epa-2021-11-19/><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The U.S. Environmental Protection Agency said the fuel economy for new vehicles hit a new high in the 2020 model year at 25.4 miles per gallon but most automakers relied on credits to meet federal ...</p>\n\n<a href=\"https://www.reuters.com/business/autos-transportation/us-vehicle-fuel-economy-hits-new-high-2020-epa-2021-11-19/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GM":"通用汽车","F":"福特汽车","TSLA":"特斯拉"},"source_url":"https://www.reuters.com/business/autos-transportation/us-vehicle-fuel-economy-hits-new-high-2020-epa-2021-11-19/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1197931355","content_text":"The U.S. Environmental Protection Agency said the fuel economy for new vehicles hit a new high in the 2020 model year at 25.4 miles per gallon but most automakers relied on credits to meet federal emissions requirements.\nThe report said since 2004, carbon dioxide emissions have decreased by 24% as fuel economy has improved by 32%.\nThe report said only Tesla Inc, Subaru and Honda met requirements without using credits. Automakers can either purchase credits or use credits earned from earlier model years.\nDetroit's Big Three automakers -- General Motors , Ford Motor Co and Chrysler parent Stellantis -- had the lowest average fleetwide fuel economy in 2020 in part because they sell more large trucks and sport utility vehicles than other automakers.\nGM and Ford both averaged 23 miles per gallon, while Stellantis averaged 21.8 mpg. Tesla, which only makes electric vehicles, led the industry, while Honda averaged 29.1 mpg, which was first among automakers building gas-powered vehicles.","news_type":1},"isVote":1,"tweetType":1,"viewCount":452,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":876966353,"gmtCreate":1637249843147,"gmtModify":1637249843231,"author":{"id":"3580791049174344","authorId":"3580791049174344","name":"windz123","avatar":"https://static.tigerbbs.com/3f5527e97f3d63e3fa0d4f05b7f5230c","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"ok","listText":"ok","text":"ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/876966353","repostId":"1125341334","repostType":4,"repost":{"id":"1125341334","pubTimestamp":1637238551,"share":"https://www.laohu8.com/m/news/1125341334?lang=&edition=full","pubTime":"2021-11-18 20:29","market":"us","language":"en","title":"Record selling by insiders is setting up stocks for a big fall, says contrarian investor ","url":"https://stock-news.laohu8.com/highlight/detail?id=1125341334","media":"MarketWatch","summary":"After a year of record stock buying on Wall Street, the message from forecasters for 2022 has largel","content":"<p>After a year of record stock buying on Wall Street, the message from forecasters for 2022 has largely been “keep at it.” This week, we heard from Goldman Sachs, which sees households and corporate buying driving the S&amp;P 500 to a 5,100 finish by the end of next year, and Sanford Bernstein, who said buy stocks even if real yields normalize, which it says justifies high valuations.</p>\n<p>A contrarian voice has been Morgan Stanley, who is telling clients to resist buying U.S. stocks. From that same neck of the woods, our <b>call of the day</b> from the&nbsp;True Contrarian blog and newsletter’s&nbsp;chief executive,&nbsp;Steven Jon Kaplan, has a warning for investors who have been piling into this market.</p>\n<p>“People are really underappreciating the degree of risk that they’re taking because now that we have — especially for the really big megacap names — even greater overvaluation than we’ve had before, the downside risk is extremely high,” Kaplan told MarketWatch in an interview on Wednesday.</p>\n<p>While a year ago Kaplan predicted a big selloff that didn’t really materialize, he notes 2021 was “unusual” with stock inflows not seen in 20 to 50 years, depending on whom you ask, that kept markets propped up. So the biggest and strongest companies kept rising and the rest went sideways.</p>\n<p>For 2022, he sees those highflying stocks falling hard and possibly panicking inexperienced investors. That is because “anybody who’s 30 years old or younger, the last time we had a bear market, they were in high school or even earlier grades so they don’t even have the experience of knowing what it’s like to invest in a bear market,” Kaplan said.</p>\n<p>Among the warning signs, he highlights a favorite indicator of his — selling and buying by company insiders, which he tracks via&nbsp;J3 Information Services Group.</p>\n<p>“We’ve had all-time record levels of insider selling meaning that the top executives, the people that are the most experienced investors in the world, have been pretty much spending all year getting rid of their stakes in some cases and unloading huge amounts of shares they have accumulated for decades,” said Kaplan.</p>\n<p>For example, the chairman of broker Charles Schwab&nbsp;who has been selling all year — the stock is up 50% — and of course Tesla&nbsp;CEO Elon Musk has dumped over $8.8 billion — shares are still up 54%. Billions have been sold by the heads of Apple,Facebook parent Meta&nbsp;and Amazon&nbsp;this year.</p>\n<p>“So I think that the people that have the most knowledge are the most worried about a drop and people that have the least experience in some cases, maybe just started trading in the past year or so, consistently, are the most aggressive and the most optimistic about what’s going to happen,” Kaplan said.</p>\n<p>“History has shown us that when you have that big a difference in opinion from the most experienced to the least experienced people that the most experienced ones always come out on top,” he said, adding that the opposite has also held true with big insiders buying at crucial moments, such as in March 2009.</p>\n<p>One sign that those investors are trying to position more conservatively could be driving dollar&nbsp;gains this year, he added.</p>\n<p>As for what it will take to normalize price earnings ratios that are on average about “triple where they need to be,” Kaplan said most stocks would need to drop two-thirds. But “when things are either above or below fair value, and they come back to fair value, they rarely stay at fair value. They normally keep going because when people start to see things dropping a lot, they start to panic,” he said.</p>\n<p>For where to park some cash for the coming storm, Kaplan suggests investors look at I-Bond or Series I savings bonds that can be bought directly from the government and are currently offering a return of 7%.</p>\n<p>“You can put up to $65,000 a year into those and for 30 years, you can just keep them in there and just let them keep collecting whatever interest that they pay, which keeps changing every six months,” he said.</p>\n<p><img src=\"https://static.tigerbbs.com/54bfe2e6578d43771146b3da16dcc260\" tg-width=\"700\" tg-height=\"462\" referrerpolicy=\"no-referrer\"></p>\n<p>Stock futures&nbsp;are pointing to a rebound from Tuesday’s selling. The Hang Seng,meanwhile, dropped 1.4% led by tech stocks. The Turkish lira&nbsp;is diving further after the country’s central bank cut interest rates 100 basis points as widely expected.</p>","source":"lsy1603348471595","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Record selling by insiders is setting up stocks for a big fall, says contrarian investor </title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRecord selling by insiders is setting up stocks for a big fall, says contrarian investor \n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-18 20:29 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.marketwatch.com/story/record-selling-by-insiders-is-setting-up-stocks-for-a-big-fall-says-contrarian-investor-11637238152?mod=home-page><strong>MarketWatch</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After a year of record stock buying on Wall Street, the message from forecasters for 2022 has largely been “keep at it.” This week, we heard from Goldman Sachs, which sees households and corporate ...</p>\n\n<a href=\"https://www.marketwatch.com/story/record-selling-by-insiders-is-setting-up-stocks-for-a-big-fall-says-contrarian-investor-11637238152?mod=home-page\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".IXIC":"NASDAQ Composite",".DJI":"道琼斯",".SPX":"S&P 500 Index"},"source_url":"https://www.marketwatch.com/story/record-selling-by-insiders-is-setting-up-stocks-for-a-big-fall-says-contrarian-investor-11637238152?mod=home-page","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1125341334","content_text":"After a year of record stock buying on Wall Street, the message from forecasters for 2022 has largely been “keep at it.” This week, we heard from Goldman Sachs, which sees households and corporate buying driving the S&P 500 to a 5,100 finish by the end of next year, and Sanford Bernstein, who said buy stocks even if real yields normalize, which it says justifies high valuations.\nA contrarian voice has been Morgan Stanley, who is telling clients to resist buying U.S. stocks. From that same neck of the woods, our call of the day from the True Contrarian blog and newsletter’s chief executive, Steven Jon Kaplan, has a warning for investors who have been piling into this market.\n“People are really underappreciating the degree of risk that they’re taking because now that we have — especially for the really big megacap names — even greater overvaluation than we’ve had before, the downside risk is extremely high,” Kaplan told MarketWatch in an interview on Wednesday.\nWhile a year ago Kaplan predicted a big selloff that didn’t really materialize, he notes 2021 was “unusual” with stock inflows not seen in 20 to 50 years, depending on whom you ask, that kept markets propped up. So the biggest and strongest companies kept rising and the rest went sideways.\nFor 2022, he sees those highflying stocks falling hard and possibly panicking inexperienced investors. That is because “anybody who’s 30 years old or younger, the last time we had a bear market, they were in high school or even earlier grades so they don’t even have the experience of knowing what it’s like to invest in a bear market,” Kaplan said.\nAmong the warning signs, he highlights a favorite indicator of his — selling and buying by company insiders, which he tracks via J3 Information Services Group.\n“We’ve had all-time record levels of insider selling meaning that the top executives, the people that are the most experienced investors in the world, have been pretty much spending all year getting rid of their stakes in some cases and unloading huge amounts of shares they have accumulated for decades,” said Kaplan.\nFor example, the chairman of broker Charles Schwab who has been selling all year — the stock is up 50% — and of course Tesla CEO Elon Musk has dumped over $8.8 billion — shares are still up 54%. Billions have been sold by the heads of Apple,Facebook parent Meta and Amazon this year.\n“So I think that the people that have the most knowledge are the most worried about a drop and people that have the least experience in some cases, maybe just started trading in the past year or so, consistently, are the most aggressive and the most optimistic about what’s going to happen,” Kaplan said.\n“History has shown us that when you have that big a difference in opinion from the most experienced to the least experienced people that the most experienced ones always come out on top,” he said, adding that the opposite has also held true with big insiders buying at crucial moments, such as in March 2009.\nOne sign that those investors are trying to position more conservatively could be driving dollar gains this year, he added.\nAs for what it will take to normalize price earnings ratios that are on average about “triple where they need to be,” Kaplan said most stocks would need to drop two-thirds. But “when things are either above or below fair value, and they come back to fair value, they rarely stay at fair value. They normally keep going because when people start to see things dropping a lot, they start to panic,” he said.\nFor where to park some cash for the coming storm, Kaplan suggests investors look at I-Bond or Series I savings bonds that can be bought directly from the government and are currently offering a return of 7%.\n“You can put up to $65,000 a year into those and for 30 years, you can just keep them in there and just let them keep collecting whatever interest that they pay, which keeps changing every six months,” he said.\n\nStock futures are pointing to a rebound from Tuesday’s selling. The Hang Seng,meanwhile, dropped 1.4% led by tech stocks. The Turkish lira is diving further after the country’s central bank cut interest rates 100 basis points as widely expected.","news_type":1},"isVote":1,"tweetType":1,"viewCount":190,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":847959913,"gmtCreate":1636474120737,"gmtModify":1636474144878,"author":{"id":"3580791049174344","authorId":"3580791049174344","name":"windz123","avatar":"https://static.tigerbbs.com/3f5527e97f3d63e3fa0d4f05b7f5230c","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"ok","listText":"ok","text":"ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/847959913","repostId":"1127189501","repostType":4,"isVote":1,"tweetType":1,"viewCount":132,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":845659700,"gmtCreate":1636336045691,"gmtModify":1636336045789,"author":{"id":"3580791049174344","authorId":"3580791049174344","name":"windz123","avatar":"https://static.tigerbbs.com/3f5527e97f3d63e3fa0d4f05b7f5230c","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"ok","listText":"ok","text":"ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/845659700","repostId":"2181284457","repostType":4,"isVote":1,"tweetType":1,"viewCount":319,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":841551327,"gmtCreate":1635927843100,"gmtModify":1635927843100,"author":{"id":"3580791049174344","authorId":"3580791049174344","name":"windz123","avatar":"https://static.tigerbbs.com/3f5527e97f3d63e3fa0d4f05b7f5230c","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"ok","listText":"ok","text":"ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/841551327","repostId":"1181104521","repostType":4,"isVote":1,"tweetType":1,"viewCount":270,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":849619135,"gmtCreate":1635750464650,"gmtModify":1635750464650,"author":{"id":"3580791049174344","authorId":"3580791049174344","name":"windz123","avatar":"https://static.tigerbbs.com/3f5527e97f3d63e3fa0d4f05b7f5230c","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/849619135","repostId":"850756569","repostType":1,"repost":{"id":850756569,"gmtCreate":1634631211448,"gmtModify":1635853120757,"author":{"id":"36984908995200","authorId":"36984908995200","name":"小虎活动","avatar":"https://static.tigerbbs.com/4f487d6799e86204e80dfde72e6040c0","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"title":"[Halloween Game] Trade or Treat!","htmlText":"Hello, dear Tigers!&nbsp; Happy&nbsp;Halloween!&nbsp;🎃🎃🎃&nbsp;&nbsp; <a href=\"https://www.tigerbrokers.com.sg/activity/market/2021/halloween/?lang=en_US#/\" target=\"_blank\">Tap&nbsp;here&nbsp;to&nbsp;play the Halloween game,&nbsp;and&nbsp;you&nbsp;stand&nbsp;a&nbsp;chance&nbsp;to win various rewards!&nbsp;</a> Promotion Period: October 27, 2021 18:00 - November 9, 2021 18:00 (SGT) 1.&nbsp;How to Participate? All Tiger clients may collect points which can be used to redeem rewards by taking part in the Trade or Treating Game. All existing Tiger clients will have 2 game attempts. Clients can get more game attempts by completing different tasks, such as 'Invite a friend' or 'Share Halloween Game'.&nbsp; 2.&nbsp;How to collect points? Each player has 30 seconds to catch falling candies while av","listText":"Hello, dear Tigers!&nbsp; Happy&nbsp;Halloween!&nbsp;🎃🎃🎃&nbsp;&nbsp; <a href=\"https://www.tigerbrokers.com.sg/activity/market/2021/halloween/?lang=en_US#/\" target=\"_blank\">Tap&nbsp;here&nbsp;to&nbsp;play the Halloween game,&nbsp;and&nbsp;you&nbsp;stand&nbsp;a&nbsp;chance&nbsp;to win various rewards!&nbsp;</a> Promotion Period: October 27, 2021 18:00 - November 9, 2021 18:00 (SGT) 1.&nbsp;How to Participate? All Tiger clients may collect points which can be used to redeem rewards by taking part in the Trade or Treating Game. All existing Tiger clients will have 2 game attempts. Clients can get more game attempts by completing different tasks, such as 'Invite a friend' or 'Share Halloween Game'.&nbsp; 2.&nbsp;How to collect points? Each player has 30 seconds to catch falling candies while av","text":"Hello, dear Tigers! Happy Halloween! 🎃🎃🎃 Tap here to play the Halloween game, and you stand a chance to win various rewards! Promotion Period: October 27, 2021 18:00 - November 9, 2021 18:00 (SGT) 1. How to Participate? All Tiger clients may collect points which can be used to redeem rewards by taking part in the Trade or Treating Game. All existing Tiger clients will have 2 game attempts. Clients can get more game attempts by completing different tasks, such as 'Invite a friend' or 'Share Halloween Game'. 2. How to collect points? Each player has 30 seconds to catch falling candies while av","images":[],"top":1,"highlighted":2,"essential":1,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/850756569","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":123,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":857937455,"gmtCreate":1635501516449,"gmtModify":1635501725504,"author":{"id":"3580791049174344","authorId":"3580791049174344","name":"windz123","avatar":"https://static.tigerbbs.com/3f5527e97f3d63e3fa0d4f05b7f5230c","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/857937455","repostId":"850756569","repostType":1,"repost":{"id":850756569,"gmtCreate":1634631211448,"gmtModify":1635853120757,"author":{"id":"36984908995200","authorId":"36984908995200","name":"小虎活动","avatar":"https://static.tigerbbs.com/4f487d6799e86204e80dfde72e6040c0","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"title":"[Halloween Game] Trade or Treat!","htmlText":"Hello, dear Tigers!&nbsp; Happy&nbsp;Halloween!&nbsp;🎃🎃🎃&nbsp;&nbsp; <a href=\"https://www.tigerbrokers.com.sg/activity/market/2021/halloween/?lang=en_US#/\" target=\"_blank\">Tap&nbsp;here&nbsp;to&nbsp;play the Halloween game,&nbsp;and&nbsp;you&nbsp;stand&nbsp;a&nbsp;chance&nbsp;to win various rewards!&nbsp;</a> Promotion Period: October 27, 2021 18:00 - November 9, 2021 18:00 (SGT) 1.&nbsp;How to Participate? All Tiger clients may collect points which can be used to redeem rewards by taking part in the Trade or Treating Game. All existing Tiger clients will have 2 game attempts. Clients can get more game attempts by completing different tasks, such as 'Invite a friend' or 'Share Halloween Game'.&nbsp; 2.&nbsp;How to collect points? Each player has 30 seconds to catch falling candies while av","listText":"Hello, dear Tigers!&nbsp; Happy&nbsp;Halloween!&nbsp;🎃🎃🎃&nbsp;&nbsp; <a href=\"https://www.tigerbrokers.com.sg/activity/market/2021/halloween/?lang=en_US#/\" target=\"_blank\">Tap&nbsp;here&nbsp;to&nbsp;play the Halloween game,&nbsp;and&nbsp;you&nbsp;stand&nbsp;a&nbsp;chance&nbsp;to win various rewards!&nbsp;</a> Promotion Period: October 27, 2021 18:00 - November 9, 2021 18:00 (SGT) 1.&nbsp;How to Participate? All Tiger clients may collect points which can be used to redeem rewards by taking part in the Trade or Treating Game. All existing Tiger clients will have 2 game attempts. Clients can get more game attempts by completing different tasks, such as 'Invite a friend' or 'Share Halloween Game'.&nbsp; 2.&nbsp;How to collect points? Each player has 30 seconds to catch falling candies while av","text":"Hello, dear Tigers! Happy Halloween! 🎃🎃🎃 Tap here to play the Halloween game, and you stand a chance to win various rewards! Promotion Period: October 27, 2021 18:00 - November 9, 2021 18:00 (SGT) 1. How to Participate? All Tiger clients may collect points which can be used to redeem rewards by taking part in the Trade or Treating Game. All existing Tiger clients will have 2 game attempts. Clients can get more game attempts by completing different tasks, such as 'Invite a friend' or 'Share Halloween Game'. 2. How to collect points? Each player has 30 seconds to catch falling candies while av","images":[],"top":1,"highlighted":2,"essential":1,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/850756569","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":254,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":825404306,"gmtCreate":1634253878720,"gmtModify":1634274402538,"author":{"id":"3580791049174344","authorId":"3580791049174344","name":"windz123","avatar":"https://static.tigerbbs.com/3f5527e97f3d63e3fa0d4f05b7f5230c","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"ok","listText":"ok","text":"ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/825404306","repostId":"1119722017","repostType":4,"repost":{"id":"1119722017","pubTimestamp":1634227887,"share":"https://www.laohu8.com/m/news/1119722017?lang=&edition=full","pubTime":"2021-10-15 00:11","market":"us","language":"en","title":"Software development platform Gitlab spikes 23% on its first day of trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1119722017","media":"Bloomberg","summary":"Software development platform Gitlab spikes 23% on its first day of trading.\n\nSoftware development p","content":"<p>Software development platform Gitlab spikes 23% on its first day of trading.</p>\n<p><img src=\"https://static.tigerbbs.com/e2c99de7182da020b44575cd1449ce5b\" tg-width=\"1828\" tg-height=\"830\" width=\"100%\" height=\"auto\"></p>\n<p>Software development platform&nbsp;Gitlab Inc.&nbsp;priced an initial public offering above a marketed range to raise $801 million.</p>\n<p>The company, along with co-founder Sytse “Sid” Sijbrandij, sold 10.4 &nbsp;million shares Wednesday for $77 each after marketing them for $66 to $69, according to astatement. Gitlab on Tuesday had elevated the price target from an earlier range of $55 to $60.</p>\n<p>At $77 a share, Gitlab has a market value of $ 11 billion based on the outstanding shares listed in its filings with the U.S. Securities and Exchange Commission. Accounting for employee stock options and restricted stock units, the company would have a fully diluted value of more than $12 billion.</p>\n<p>Sijbrandij, the company’s chief executive officer, had planned to sell 1.98 million shares, which would be worth $152 million at the IPO price. Investors in the company include funds and affiliates of&nbsp;August Capital, Alphabet Inc.’s GV,Iconiq Capital&nbsp;and&nbsp;Khosla Ventures, according to the filings.</p>\n<p>Gitlab provides collaboration tools used by software developers and competes with Microsoft Corp.’s Github.Goldman Sachs Group Inc., UBS Group AG, Siemens AG and ZipRecruiter Inc. are among its customers.</p>\n<p><b>Remote-Only Company</b></p>\n<p>Though incorporated in Delaware in 2014, GitLab operates as a remote-only company and doesn’t have a corporate office, according to its filings. Its 1,350 team members are located in more than 65 countries.</p>\n<p>The company had a net loss of $69 million on revenue of $108 million for the six months ending July 31, according to its filings. That compared with a $44 million loss on $64 million in revenue during the same period the previous year.</p>\n<p>Proceeds of the offering will be used for general corporate purposes and working capital, according to its filings. The main purpose of the listing is to provide a public market for its shares and to increase the visibility of the company, the company said in the prospectus.</p>\n<p>The offering is being led by Goldman Sachs,JP&nbsp;Morgan Chase &amp; Co.and&nbsp;Bank of America Corp. The shares are expected to begin trading Thursday on the Nasdaq Global Market under the symbol GTLB.</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Software development platform Gitlab spikes 23% on its first day of trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSoftware development platform Gitlab spikes 23% on its first day of trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-15 00:11 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-10-14/gitlab-exceeds-ipo-target-price-to-raise-801-million><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Software development platform Gitlab spikes 23% on its first day of trading.\n\nSoftware development platform Gitlab Inc. priced an initial public offering above a marketed range to raise $801 million.\n...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-10-14/gitlab-exceeds-ipo-target-price-to-raise-801-million\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GTLB":"GitLab, Inc."},"source_url":"https://www.bloomberg.com/news/articles/2021-10-14/gitlab-exceeds-ipo-target-price-to-raise-801-million","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1119722017","content_text":"Software development platform Gitlab spikes 23% on its first day of trading.\n\nSoftware development platform Gitlab Inc. priced an initial public offering above a marketed range to raise $801 million.\nThe company, along with co-founder Sytse “Sid” Sijbrandij, sold 10.4  million shares Wednesday for $77 each after marketing them for $66 to $69, according to astatement. Gitlab on Tuesday had elevated the price target from an earlier range of $55 to $60.\nAt $77 a share, Gitlab has a market value of $ 11 billion based on the outstanding shares listed in its filings with the U.S. Securities and Exchange Commission. Accounting for employee stock options and restricted stock units, the company would have a fully diluted value of more than $12 billion.\nSijbrandij, the company’s chief executive officer, had planned to sell 1.98 million shares, which would be worth $152 million at the IPO price. Investors in the company include funds and affiliates of August Capital, Alphabet Inc.’s GV,Iconiq Capital and Khosla Ventures, according to the filings.\nGitlab provides collaboration tools used by software developers and competes with Microsoft Corp.’s Github.Goldman Sachs Group Inc., UBS Group AG, Siemens AG and ZipRecruiter Inc. are among its customers.\nRemote-Only Company\nThough incorporated in Delaware in 2014, GitLab operates as a remote-only company and doesn’t have a corporate office, according to its filings. Its 1,350 team members are located in more than 65 countries.\nThe company had a net loss of $69 million on revenue of $108 million for the six months ending July 31, according to its filings. That compared with a $44 million loss on $64 million in revenue during the same period the previous year.\nProceeds of the offering will be used for general corporate purposes and working capital, according to its filings. The main purpose of the listing is to provide a public market for its shares and to increase the visibility of the company, the company said in the prospectus.\nThe offering is being led by Goldman Sachs,JP Morgan Chase & Co.and Bank of America Corp. The shares are expected to begin trading Thursday on the Nasdaq Global Market under the symbol GTLB.","news_type":1},"isVote":1,"tweetType":1,"viewCount":185,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":602194376,"gmtCreate":1638978900994,"gmtModify":1638978901060,"author":{"id":"3580791049174344","authorId":"3580791049174344","name":"windz123","avatar":"https://static.tigerbbs.com/3f5527e97f3d63e3fa0d4f05b7f5230c","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"ok","listText":"ok","text":"ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/602194376","repostId":"1147964036","repostType":4,"repost":{"id":"1147964036","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638975024,"share":"https://www.laohu8.com/m/news/1147964036?lang=&edition=full","pubTime":"2021-12-08 22:50","market":"us","language":"en","title":"NXP Semi stock dipped 5% in morning trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1147964036","media":"Tiger Newspress","summary":"Shares of NXP Semiconductors fell 5% Wednesday after UBS initiated coverage on the stock with a Sell","content":"<p>Shares of&nbsp;NXP Semiconductors&nbsp;fell 5%&nbsp;Wednesday after UBS initiated coverage on the stock with a Sell rating and $170 price target.</p>\n<p><img src=\"https://static.tigerbbs.com/b5d453dfd0ee36431831e571e251cd18\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\"></p>\n<p>UBS said it expects growth at the company’s automotive division to “underperform the auto semis market.”</p>\n<p>“While we believe NXP (ticker: NXPI) will remain a leader in its product categories with a solid business, we expect the automotive division’s growth (50% of revenues) to underperform the automotive semis market, due predominantly to a relatively lower content opportunity in EVs vs. peers” such as&nbsp;ON Semiconductor&nbsp;and&nbsp;Infineon,UBS said in a research note Wednesday.</p>\n<p>The analysts, led by Francois-Xavier Bouvignies, also said the company’s “industrial/IoT and Mobile divisions deserve a discount due to high fragmentation and high disruption risks.”</p>\n<p>Analysts surveyed by FactSet rate the stock, on average, at Overweight with a price target of $242.20.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>NXP Semi stock dipped 5% in morning trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNXP Semi stock dipped 5% in morning trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-08 22:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of&nbsp;NXP Semiconductors&nbsp;fell 5%&nbsp;Wednesday after UBS initiated coverage on the stock with a Sell rating and $170 price target.</p>\n<p><img src=\"https://static.tigerbbs.com/b5d453dfd0ee36431831e571e251cd18\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\"></p>\n<p>UBS said it expects growth at the company’s automotive division to “underperform the auto semis market.”</p>\n<p>“While we believe NXP (ticker: NXPI) will remain a leader in its product categories with a solid business, we expect the automotive division’s growth (50% of revenues) to underperform the automotive semis market, due predominantly to a relatively lower content opportunity in EVs vs. peers” such as&nbsp;ON Semiconductor&nbsp;and&nbsp;Infineon,UBS said in a research note Wednesday.</p>\n<p>The analysts, led by Francois-Xavier Bouvignies, also said the company’s “industrial/IoT and Mobile divisions deserve a discount due to high fragmentation and high disruption risks.”</p>\n<p>Analysts surveyed by FactSet rate the stock, on average, at Overweight with a price target of $242.20.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NXPI":"恩智浦"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1147964036","content_text":"Shares of NXP Semiconductors fell 5% Wednesday after UBS initiated coverage on the stock with a Sell rating and $170 price target.\n\nUBS said it expects growth at the company’s automotive division to “underperform the auto semis market.”\n“While we believe NXP (ticker: NXPI) will remain a leader in its product categories with a solid business, we expect the automotive division’s growth (50% of revenues) to underperform the automotive semis market, due predominantly to a relatively lower content opportunity in EVs vs. peers” such as ON Semiconductor and Infineon,UBS said in a research note Wednesday.\nThe analysts, led by Francois-Xavier Bouvignies, also said the company’s “industrial/IoT and Mobile divisions deserve a discount due to high fragmentation and high disruption risks.”\nAnalysts surveyed by FactSet rate the stock, on average, at Overweight with a price target of $242.20.","news_type":1},"isVote":1,"tweetType":1,"viewCount":596,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":841551327,"gmtCreate":1635927843100,"gmtModify":1635927843100,"author":{"id":"3580791049174344","authorId":"3580791049174344","name":"windz123","avatar":"https://static.tigerbbs.com/3f5527e97f3d63e3fa0d4f05b7f5230c","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"ok","listText":"ok","text":"ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/841551327","repostId":"1181104521","repostType":4,"repost":{"id":"1181104521","pubTimestamp":1635927380,"share":"https://www.laohu8.com/m/news/1181104521?lang=&edition=full","pubTime":"2021-11-03 16:16","market":"us","language":"en","title":"71 Biggest Movers From Yesterday","url":"https://stock-news.laohu8.com/highlight/detail?id=1181104521","media":"Benzinga","summary":"Gainers\n\nAvis Budget Group, Inc. shares climbed 108.3% to close at $357.17 on Tuesday after the comp","content":"<p>Gainers</p>\n<ul>\n <li><b>Avis Budget Group, Inc.</b>&nbsp;shares climbed 108.3% to close at $357.17 on Tuesday after the company reported better-than-expected Q3 adjusted EPS and sales results and added $1 billion to its buyback.</li>\n <li><b>The OLB Group, Inc.</b>&nbsp;shares gained 87.4% to settle at $8.60 after the company announced support for Mastercard cryptocurrency processing.</li>\n <li><b>Huadi International Group Co., Ltd.</b>&nbsp;jumped 29.8% to close at $24.31. Huadi International Group was recently awarded a $3.26 million stainless steel seamless pipe order contracts from a U.S. client.</li>\n <li><b>Rogers Corporation</b>&nbsp;surged 29.6% to close at $269.90 after the company announced it will be acquired by DuPont for $277 per share in cash. Rogers also released Q3 results.</li>\n <li><b>Esports Entertainment Group, Inc.</b>&nbsp;gained 29% to settle at $7.57. Roth Capital initiated coverage on Esports Entertainment with a Buy rating and announced a price target of $22.</li>\n <li><b>Cassava Sciences, Inc.</b>&nbsp;jumped 25.9% to close at $58.07.</li>\n <li><b>Net Element, Inc.</b>&nbsp;gained 24.2% to settle at $11.09. Net Element’s reverse merger partner Mullen Automotive announced plans to expand Robinsonville, Mississippi site.</li>\n <li><b>Compass Therapeutics, Inc.</b>&nbsp;shares rose 24% to close at $3.98. Compass Therapeutics reported pricing of approximately $125 million public offering of common stock and uplisting to the Nasdaq Capital Market.</li>\n <li><b>FG Financial Group, Inc.</b>&nbsp;gained 24% to close at $6.30.</li>\n <li><b>Stronghold Digital Mining, Inc.</b>&nbsp;surged 22% to settle at $33.26. The company recently priced its IPO at $19 per share.</li>\n <li><b>Xilio Therapeutics, Inc.</b>&nbsp;jumped 21.4% to close at $23.09.</li>\n <li><b>Icosavax, Inc.</b>&nbsp;gained 20.5% to settle at $34.98.</li>\n <li><b>Arista Networks, Inc.</b>&nbsp;gained 20.4% to close at $491.87 as the company reported better-than-expected results for its third quarter and issued strong sales forecast for the fourth quarter. The company announced a four-for-one stock split and also disclosed a $1 billion stock-buyback plan.</li>\n <li><b>Baosheng Media Group Holdings Limited</b>&nbsp;jumped 20.3% to close at $1.90 after declining 3% on Monday. The company, last month, swung to a loss in the first half of the year.</li>\n <li><b>Cortexyme, Inc.</b>&nbsp;jumped 19.5% to close at $16.98. Cortexyme recently said that the company's Phase 2/3 GAIN trial did not meet its co-primary endpoints.</li>\n <li><b>Phunware, Inc.</b>&nbsp;rose 19.3% to settle at $4.57. Phunware is expected to a conference call on Thursday, November 11, 2021 to discuss its financial results for the third quarter ended September 30, 2021.</li>\n <li><b>Kiniksa Pharmaceuticals, Ltd.</b>&nbsp;jumped 19% to close at $15.15. The company recently posted upbeat quarterly results.</li>\n <li><b>DZS Inc.</b>&nbsp;gained 18.6% to close at $13.22 following upbeat Q3 results.</li>\n <li><b>Materion Corporation</b>&nbsp;jumped 16.8% to settle at $86.44 following better-than-expected quarterly results.</li>\n <li><b>Under Armour, Inc.</b>&nbsp;climbed 16.5% to close at $25.60 after the company reported better-than-expected Q3 EPS and sales results and raised guidance.</li>\n <li><b>SilverBox Engaged Merger Corp I</b>&nbsp;climbed 15.4% to close at $11.33 after the company announced a business combination with Black Rifle Coffee Company.</li>\n <li><b>Tanger Factory Outlet Centers, Inc.</b>&nbsp;gained 15.3% to settle at $20.45 following Q3 results.</li>\n <li><b>View, Inc.</b>&nbsp;rose 15.3% to settle at $6.10.</li>\n <li><b>Bitfarms Ltd.</b>&nbsp;gained 15.1% to close at $6.41 amid a rise in the price of Bitcoin and Ethereum.</li>\n <li><b>Toast, Inc.</b>&nbsp;shares jumped 14.1% to settle at $65.22.</li>\n <li><b>The Macerich Company</b>&nbsp;gained 13.4% to settle at $21.40.</li>\n <li><b>Fabrinet</b>&nbsp;climbed 13.2% to close at $111.21 after the company reported better-than-expected Q1 EPS and sales results. The company also issued Q2 guidance.</li>\n <li><b>NetScout Systems, Inc.</b>&nbsp;gained 13.1% to settle at $31.97 after it was announced the company will be joining the SmallCap 600.</li>\n <li><b>Harmonic Inc.</b>&nbsp;climbed 12.5% to close at $10.50 after the company reported better-than-expected Q3 EPS and sales results and issued Q4 net sales guidance and FY21 adjusted EPS and net sales guidance above estimates.</li>\n <li><b>Silicom Ltd.</b>&nbsp;climbed 11.5% to close at $46.72. Silicom received $30 million purchase orders from leading American service provider for Silicom Smart Edge Platforms.</li>\n <li><b>Sequans Communications S.A.</b>&nbsp;shares gained 10.3% to close at $5.13 following narrower-than-expected quarterly loss.</li>\n <li><b>Extreme Networks, Inc.</b>&nbsp;gained 10.2% to settle at $11.37 following upbeat quarterly results.</li>\n <li><b>Endo International plc</b>&nbsp;rose 9.7% to close at $5.08 after the company reported the California state court issued a tentative ruling in Endo's favor following the opioid trial.</li>\n <li><b>Teva Pharmaceutical Industries Limited</b>&nbsp;rose 9.5% to close at $10.11 after the company reported a California judge ruled that Teva did not cause a public nuisance or make false or misleading statements about opioids.</li>\n <li><b>SAB Biotherapeutics, Inc.</b>&nbsp;rose 8.8% to close at $9.17 as traders circulated a new Outperform rating and $23 price target on stock.</li>\n <li><b>Navitas Semiconductor Corporation</b>&nbsp;gained 7.7% to settle at $14.00.</li>\n <li><b>AutoWeb, Inc.</b>&nbsp;rose 7.1% to close at $3.45.</li>\n <li><b>HyreCar Inc.</b>&nbsp;gained 6.5% to close at $7.54.</li>\n</ul>\n<p><b>Losers</b></p>\n<ul>\n <li><b>Birks Group Inc.</b>&nbsp;shares fell 51.7% to settle at $3.77 on Tuesday.</li>\n <li><b>Chegg, Inc.</b>&nbsp;shares tumbled 48.8% to close at $32.12 on Tuesday after the company reported worse-than-expected Q3 sales results and issued Q4 and FY21 sales guidance below estimates. Various analysts also downgraded the stock.</li>\n <li><b>Mountain Crest Acquisition Corp. II</b>&nbsp;dropped 32.9% to settle at $11.50. Better Therapeutics recently completed its merger with Mountain Crest Acquisition Corp II.</li>\n <li><b>Triterras, Inc.</b>&nbsp;fell 27.4% to close at $5.43 after B. Riley Securities downgraded the stock from Buy to Neutral and lowers its price target from $9 to $5. Also, the company reported it did not meet Nasdaq's Nov. 1 deadline to file its annual report on Form 20-F with the SEC.</li>\n <li><b>ABVC BioPharma, Inc.</b>&nbsp;dipped 26.2% to settle at $4.45 after climbing 137% on Monday.</li>\n <li><b>Semler Scientific, Inc.</b>&nbsp;declined 25.4% to close at $111.66 after the company reported worse-than-expected Q3 results.</li>\n <li><b>The Pennant Group, Inc.</b>&nbsp;fell 23.3% to close at $20.80. The company sees preliminary Q3 total revenue of $111.9 million and net income of $1.2 million.</li>\n <li><b>Spartacus Acquisition Corporation</b>&nbsp;shares fell 22% to close at $9.97 after jumping more than 16% on Monday.</li>\n <li><b>CONSOL Energy Inc.</b>&nbsp;fell 21.6% to close at $22.24 following weak quarterly sales.</li>\n <li><b>Harsco Corporation</b>&nbsp;declined 20.2% to settle at $14.49 after the company reported downbeat Q3 results and announced plans to explore strategic alternatives for rail business.</li>\n <li><b>Switchback II Corporation</b>&nbsp;fell 18.3% to close at $8.17.</li>\n <li><b>Intrepid Potash, Inc.</b>&nbsp;dropped 17.6% to close at $42.26 following downbeat Q3 earnings.</li>\n <li><b>Sabre Corporation</b>&nbsp;fell 16.6% to settle at $9.01 after the company reported worse-than-expected Q3 sales results. The company did not give guidance due to the COVID-19 pandemic.</li>\n <li><b>HCW Biologics Inc.</b>&nbsp;dipped 15.9% to close at $3.29.</li>\n <li><b>Guardforce AI Co., Limited</b>&nbsp;fell 15.5% to close at $2.23. Guardforce recently announced it has engaged MZ Group, an investor relations company, to ' lead a comprehensive strategic investor relations and financial communications program.'</li>\n <li><b>Super League Gaming, Inc.</b>&nbsp;dropped 15.2% to close at $3.24.</li>\n <li><b>Opendoor Technologies Inc.</b>&nbsp;dipped 14.7% to settle at $21.12.</li>\n <li><b>Muscle Maker, Inc.</b>&nbsp;shares declined 13.8% to settle at $1.44 after gaining over 50% on Monday. Muscle Maker inked a Master Franchise Agreement for 40 units in the Kingdom of Saudi Arabia.</li>\n <li><b>MoneyGram International, Inc.</b>&nbsp;fell 13.7% to close at $5.28.</li>\n <li><b>CVR Energy, Inc.</b>&nbsp;fell 13.3% to settle at $17.19 after reporting a wider-than-expected quarterly loss.</li>\n <li><b>Clene Inc.</b>&nbsp;fell 12.7% to settle at $4.80 after the company announced its RESCUE-ALS Phase 2 did not meet its primary or secondary endpoint.</li>\n <li><b>EverQuote, Inc.</b>&nbsp;declined 12.1% to close at $12.60 following Q3 results. JP Morgan downgraded EverQuote from Overweight to Neutral and lowered the price target from $41 to $17.</li>\n <li><b>Cohen &amp; Company Inc.</b>&nbsp;fell 11.9% to close at $18.84 after reporting a Q3 loss.</li>\n <li><b>Zillow Group, Inc.</b>&nbsp;shares fell 10.2% to settle at $87.20 after KeyBanc analysts said they believe the company's earnings may be at risk due to its $1.17 billion home inventory, finding that 66% of these homes are listed below their purchase price.</li>\n <li><b>Neurocrine Biosciences, Inc.</b>&nbsp;dropped 10% to close at $95.58 following weak quarterly sales.</li>\n <li><b>LSB Industries, Inc.</b>&nbsp;fell 10% to close at $8.69 following weak quarterly sales.</li>\n <li><b>Invacare Corporation</b>&nbsp;fell 9.8% to close at $4.34. NetScout Systems will join S&amp;P SmallCap 600, will replace Invacare.</li>\n <li><b>Leggett &amp; Platt, Incorporated</b>&nbsp;dropped 9.5% to close at $43.54 after the company reported worse-than-expected Q3 EPS results.</li>\n <li><b>Lightbridge Corporation</b>&nbsp;fell 9.2% to settle at $10.58.</li>\n <li><b>Global Payments Inc.</b>&nbsp;fell 9.2% to close at $132.35 after the company reported Q3 earnings results and issued guidance.</li>\n <li><b>Cipher Mining Inc.</b>&nbsp;fell 8.7% to close at $8.99 after jumping 25% on Monday.</li>\n <li><b>ADC Therapeutics SA</b>&nbsp;fell 7.4% to close at $29.18 after reporting Q3 results.</li>\n <li><b>Puhui Wealth Investment Management Co., Ltd.</b>&nbsp;fell 7.2% to close at $1.93 after climbing more than 15% on Monday.</li>\n</ul>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>71 Biggest Movers From Yesterday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n71 Biggest Movers From Yesterday\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-03 16:16 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/news/21/11/23848466/71-biggest-movers-from-yesterday><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Gainers\n\nAvis Budget Group, Inc. shares climbed 108.3% to close at $357.17 on Tuesday after the company reported better-than-expected Q3 adjusted EPS and sales results and added $1 billion to its ...</p>\n\n<a href=\"https://www.benzinga.com/news/21/11/23848466/71-biggest-movers-from-yesterday\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ROG":"罗杰斯"},"source_url":"https://www.benzinga.com/news/21/11/23848466/71-biggest-movers-from-yesterday","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1181104521","content_text":"Gainers\n\nAvis Budget Group, Inc. shares climbed 108.3% to close at $357.17 on Tuesday after the company reported better-than-expected Q3 adjusted EPS and sales results and added $1 billion to its buyback.\nThe OLB Group, Inc. shares gained 87.4% to settle at $8.60 after the company announced support for Mastercard cryptocurrency processing.\nHuadi International Group Co., Ltd. jumped 29.8% to close at $24.31. Huadi International Group was recently awarded a $3.26 million stainless steel seamless pipe order contracts from a U.S. client.\nRogers Corporation surged 29.6% to close at $269.90 after the company announced it will be acquired by DuPont for $277 per share in cash. Rogers also released Q3 results.\nEsports Entertainment Group, Inc. gained 29% to settle at $7.57. Roth Capital initiated coverage on Esports Entertainment with a Buy rating and announced a price target of $22.\nCassava Sciences, Inc. jumped 25.9% to close at $58.07.\nNet Element, Inc. gained 24.2% to settle at $11.09. Net Element’s reverse merger partner Mullen Automotive announced plans to expand Robinsonville, Mississippi site.\nCompass Therapeutics, Inc. shares rose 24% to close at $3.98. Compass Therapeutics reported pricing of approximately $125 million public offering of common stock and uplisting to the Nasdaq Capital Market.\nFG Financial Group, Inc. gained 24% to close at $6.30.\nStronghold Digital Mining, Inc. surged 22% to settle at $33.26. The company recently priced its IPO at $19 per share.\nXilio Therapeutics, Inc. jumped 21.4% to close at $23.09.\nIcosavax, Inc. gained 20.5% to settle at $34.98.\nArista Networks, Inc. gained 20.4% to close at $491.87 as the company reported better-than-expected results for its third quarter and issued strong sales forecast for the fourth quarter. The company announced a four-for-one stock split and also disclosed a $1 billion stock-buyback plan.\nBaosheng Media Group Holdings Limited jumped 20.3% to close at $1.90 after declining 3% on Monday. The company, last month, swung to a loss in the first half of the year.\nCortexyme, Inc. jumped 19.5% to close at $16.98. Cortexyme recently said that the company's Phase 2/3 GAIN trial did not meet its co-primary endpoints.\nPhunware, Inc. rose 19.3% to settle at $4.57. Phunware is expected to a conference call on Thursday, November 11, 2021 to discuss its financial results for the third quarter ended September 30, 2021.\nKiniksa Pharmaceuticals, Ltd. jumped 19% to close at $15.15. The company recently posted upbeat quarterly results.\nDZS Inc. gained 18.6% to close at $13.22 following upbeat Q3 results.\nMaterion Corporation jumped 16.8% to settle at $86.44 following better-than-expected quarterly results.\nUnder Armour, Inc. climbed 16.5% to close at $25.60 after the company reported better-than-expected Q3 EPS and sales results and raised guidance.\nSilverBox Engaged Merger Corp I climbed 15.4% to close at $11.33 after the company announced a business combination with Black Rifle Coffee Company.\nTanger Factory Outlet Centers, Inc. gained 15.3% to settle at $20.45 following Q3 results.\nView, Inc. rose 15.3% to settle at $6.10.\nBitfarms Ltd. gained 15.1% to close at $6.41 amid a rise in the price of Bitcoin and Ethereum.\nToast, Inc. shares jumped 14.1% to settle at $65.22.\nThe Macerich Company gained 13.4% to settle at $21.40.\nFabrinet climbed 13.2% to close at $111.21 after the company reported better-than-expected Q1 EPS and sales results. The company also issued Q2 guidance.\nNetScout Systems, Inc. gained 13.1% to settle at $31.97 after it was announced the company will be joining the SmallCap 600.\nHarmonic Inc. climbed 12.5% to close at $10.50 after the company reported better-than-expected Q3 EPS and sales results and issued Q4 net sales guidance and FY21 adjusted EPS and net sales guidance above estimates.\nSilicom Ltd. climbed 11.5% to close at $46.72. Silicom received $30 million purchase orders from leading American service provider for Silicom Smart Edge Platforms.\nSequans Communications S.A. shares gained 10.3% to close at $5.13 following narrower-than-expected quarterly loss.\nExtreme Networks, Inc. gained 10.2% to settle at $11.37 following upbeat quarterly results.\nEndo International plc rose 9.7% to close at $5.08 after the company reported the California state court issued a tentative ruling in Endo's favor following the opioid trial.\nTeva Pharmaceutical Industries Limited rose 9.5% to close at $10.11 after the company reported a California judge ruled that Teva did not cause a public nuisance or make false or misleading statements about opioids.\nSAB Biotherapeutics, Inc. rose 8.8% to close at $9.17 as traders circulated a new Outperform rating and $23 price target on stock.\nNavitas Semiconductor Corporation gained 7.7% to settle at $14.00.\nAutoWeb, Inc. rose 7.1% to close at $3.45.\nHyreCar Inc. gained 6.5% to close at $7.54.\n\nLosers\n\nBirks Group Inc. shares fell 51.7% to settle at $3.77 on Tuesday.\nChegg, Inc. shares tumbled 48.8% to close at $32.12 on Tuesday after the company reported worse-than-expected Q3 sales results and issued Q4 and FY21 sales guidance below estimates. Various analysts also downgraded the stock.\nMountain Crest Acquisition Corp. II dropped 32.9% to settle at $11.50. Better Therapeutics recently completed its merger with Mountain Crest Acquisition Corp II.\nTriterras, Inc. fell 27.4% to close at $5.43 after B. Riley Securities downgraded the stock from Buy to Neutral and lowers its price target from $9 to $5. Also, the company reported it did not meet Nasdaq's Nov. 1 deadline to file its annual report on Form 20-F with the SEC.\nABVC BioPharma, Inc. dipped 26.2% to settle at $4.45 after climbing 137% on Monday.\nSemler Scientific, Inc. declined 25.4% to close at $111.66 after the company reported worse-than-expected Q3 results.\nThe Pennant Group, Inc. fell 23.3% to close at $20.80. The company sees preliminary Q3 total revenue of $111.9 million and net income of $1.2 million.\nSpartacus Acquisition Corporation shares fell 22% to close at $9.97 after jumping more than 16% on Monday.\nCONSOL Energy Inc. fell 21.6% to close at $22.24 following weak quarterly sales.\nHarsco Corporation declined 20.2% to settle at $14.49 after the company reported downbeat Q3 results and announced plans to explore strategic alternatives for rail business.\nSwitchback II Corporation fell 18.3% to close at $8.17.\nIntrepid Potash, Inc. dropped 17.6% to close at $42.26 following downbeat Q3 earnings.\nSabre Corporation fell 16.6% to settle at $9.01 after the company reported worse-than-expected Q3 sales results. The company did not give guidance due to the COVID-19 pandemic.\nHCW Biologics Inc. dipped 15.9% to close at $3.29.\nGuardforce AI Co., Limited fell 15.5% to close at $2.23. Guardforce recently announced it has engaged MZ Group, an investor relations company, to ' lead a comprehensive strategic investor relations and financial communications program.'\nSuper League Gaming, Inc. dropped 15.2% to close at $3.24.\nOpendoor Technologies Inc. dipped 14.7% to settle at $21.12.\nMuscle Maker, Inc. shares declined 13.8% to settle at $1.44 after gaining over 50% on Monday. Muscle Maker inked a Master Franchise Agreement for 40 units in the Kingdom of Saudi Arabia.\nMoneyGram International, Inc. fell 13.7% to close at $5.28.\nCVR Energy, Inc. fell 13.3% to settle at $17.19 after reporting a wider-than-expected quarterly loss.\nClene Inc. fell 12.7% to settle at $4.80 after the company announced its RESCUE-ALS Phase 2 did not meet its primary or secondary endpoint.\nEverQuote, Inc. declined 12.1% to close at $12.60 following Q3 results. JP Morgan downgraded EverQuote from Overweight to Neutral and lowered the price target from $41 to $17.\nCohen & Company Inc. fell 11.9% to close at $18.84 after reporting a Q3 loss.\nZillow Group, Inc. shares fell 10.2% to settle at $87.20 after KeyBanc analysts said they believe the company's earnings may be at risk due to its $1.17 billion home inventory, finding that 66% of these homes are listed below their purchase price.\nNeurocrine Biosciences, Inc. dropped 10% to close at $95.58 following weak quarterly sales.\nLSB Industries, Inc. fell 10% to close at $8.69 following weak quarterly sales.\nInvacare Corporation fell 9.8% to close at $4.34. NetScout Systems will join S&P SmallCap 600, will replace Invacare.\nLeggett & Platt, Incorporated dropped 9.5% to close at $43.54 after the company reported worse-than-expected Q3 EPS results.\nLightbridge Corporation fell 9.2% to settle at $10.58.\nGlobal Payments Inc. fell 9.2% to close at $132.35 after the company reported Q3 earnings results and issued guidance.\nCipher Mining Inc. fell 8.7% to close at $8.99 after jumping 25% on Monday.\nADC Therapeutics SA fell 7.4% to close at $29.18 after reporting Q3 results.\nPuhui Wealth Investment Management Co., Ltd. fell 7.2% to close at $1.93 after climbing more than 15% on Monday.","news_type":1},"isVote":1,"tweetType":1,"viewCount":270,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":876966353,"gmtCreate":1637249843147,"gmtModify":1637249843231,"author":{"id":"3580791049174344","authorId":"3580791049174344","name":"windz123","avatar":"https://static.tigerbbs.com/3f5527e97f3d63e3fa0d4f05b7f5230c","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"ok","listText":"ok","text":"ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/876966353","repostId":"1125341334","repostType":4,"repost":{"id":"1125341334","pubTimestamp":1637238551,"share":"https://www.laohu8.com/m/news/1125341334?lang=&edition=full","pubTime":"2021-11-18 20:29","market":"us","language":"en","title":"Record selling by insiders is setting up stocks for a big fall, says contrarian investor ","url":"https://stock-news.laohu8.com/highlight/detail?id=1125341334","media":"MarketWatch","summary":"After a year of record stock buying on Wall Street, the message from forecasters for 2022 has largel","content":"<p>After a year of record stock buying on Wall Street, the message from forecasters for 2022 has largely been “keep at it.” This week, we heard from Goldman Sachs, which sees households and corporate buying driving the S&amp;P 500 to a 5,100 finish by the end of next year, and Sanford Bernstein, who said buy stocks even if real yields normalize, which it says justifies high valuations.</p>\n<p>A contrarian voice has been Morgan Stanley, who is telling clients to resist buying U.S. stocks. From that same neck of the woods, our <b>call of the day</b> from the&nbsp;True Contrarian blog and newsletter’s&nbsp;chief executive,&nbsp;Steven Jon Kaplan, has a warning for investors who have been piling into this market.</p>\n<p>“People are really underappreciating the degree of risk that they’re taking because now that we have — especially for the really big megacap names — even greater overvaluation than we’ve had before, the downside risk is extremely high,” Kaplan told MarketWatch in an interview on Wednesday.</p>\n<p>While a year ago Kaplan predicted a big selloff that didn’t really materialize, he notes 2021 was “unusual” with stock inflows not seen in 20 to 50 years, depending on whom you ask, that kept markets propped up. So the biggest and strongest companies kept rising and the rest went sideways.</p>\n<p>For 2022, he sees those highflying stocks falling hard and possibly panicking inexperienced investors. That is because “anybody who’s 30 years old or younger, the last time we had a bear market, they were in high school or even earlier grades so they don’t even have the experience of knowing what it’s like to invest in a bear market,” Kaplan said.</p>\n<p>Among the warning signs, he highlights a favorite indicator of his — selling and buying by company insiders, which he tracks via&nbsp;J3 Information Services Group.</p>\n<p>“We’ve had all-time record levels of insider selling meaning that the top executives, the people that are the most experienced investors in the world, have been pretty much spending all year getting rid of their stakes in some cases and unloading huge amounts of shares they have accumulated for decades,” said Kaplan.</p>\n<p>For example, the chairman of broker Charles Schwab&nbsp;who has been selling all year — the stock is up 50% — and of course Tesla&nbsp;CEO Elon Musk has dumped over $8.8 billion — shares are still up 54%. Billions have been sold by the heads of Apple,Facebook parent Meta&nbsp;and Amazon&nbsp;this year.</p>\n<p>“So I think that the people that have the most knowledge are the most worried about a drop and people that have the least experience in some cases, maybe just started trading in the past year or so, consistently, are the most aggressive and the most optimistic about what’s going to happen,” Kaplan said.</p>\n<p>“History has shown us that when you have that big a difference in opinion from the most experienced to the least experienced people that the most experienced ones always come out on top,” he said, adding that the opposite has also held true with big insiders buying at crucial moments, such as in March 2009.</p>\n<p>One sign that those investors are trying to position more conservatively could be driving dollar&nbsp;gains this year, he added.</p>\n<p>As for what it will take to normalize price earnings ratios that are on average about “triple where they need to be,” Kaplan said most stocks would need to drop two-thirds. But “when things are either above or below fair value, and they come back to fair value, they rarely stay at fair value. They normally keep going because when people start to see things dropping a lot, they start to panic,” he said.</p>\n<p>For where to park some cash for the coming storm, Kaplan suggests investors look at I-Bond or Series I savings bonds that can be bought directly from the government and are currently offering a return of 7%.</p>\n<p>“You can put up to $65,000 a year into those and for 30 years, you can just keep them in there and just let them keep collecting whatever interest that they pay, which keeps changing every six months,” he said.</p>\n<p><img src=\"https://static.tigerbbs.com/54bfe2e6578d43771146b3da16dcc260\" tg-width=\"700\" tg-height=\"462\" referrerpolicy=\"no-referrer\"></p>\n<p>Stock futures&nbsp;are pointing to a rebound from Tuesday’s selling. The Hang Seng,meanwhile, dropped 1.4% led by tech stocks. The Turkish lira&nbsp;is diving further after the country’s central bank cut interest rates 100 basis points as widely expected.</p>","source":"lsy1603348471595","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Record selling by insiders is setting up stocks for a big fall, says contrarian investor </title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRecord selling by insiders is setting up stocks for a big fall, says contrarian investor \n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-18 20:29 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.marketwatch.com/story/record-selling-by-insiders-is-setting-up-stocks-for-a-big-fall-says-contrarian-investor-11637238152?mod=home-page><strong>MarketWatch</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After a year of record stock buying on Wall Street, the message from forecasters for 2022 has largely been “keep at it.” This week, we heard from Goldman Sachs, which sees households and corporate ...</p>\n\n<a href=\"https://www.marketwatch.com/story/record-selling-by-insiders-is-setting-up-stocks-for-a-big-fall-says-contrarian-investor-11637238152?mod=home-page\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".IXIC":"NASDAQ Composite",".DJI":"道琼斯",".SPX":"S&P 500 Index"},"source_url":"https://www.marketwatch.com/story/record-selling-by-insiders-is-setting-up-stocks-for-a-big-fall-says-contrarian-investor-11637238152?mod=home-page","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1125341334","content_text":"After a year of record stock buying on Wall Street, the message from forecasters for 2022 has largely been “keep at it.” This week, we heard from Goldman Sachs, which sees households and corporate buying driving the S&P 500 to a 5,100 finish by the end of next year, and Sanford Bernstein, who said buy stocks even if real yields normalize, which it says justifies high valuations.\nA contrarian voice has been Morgan Stanley, who is telling clients to resist buying U.S. stocks. From that same neck of the woods, our call of the day from the True Contrarian blog and newsletter’s chief executive, Steven Jon Kaplan, has a warning for investors who have been piling into this market.\n“People are really underappreciating the degree of risk that they’re taking because now that we have — especially for the really big megacap names — even greater overvaluation than we’ve had before, the downside risk is extremely high,” Kaplan told MarketWatch in an interview on Wednesday.\nWhile a year ago Kaplan predicted a big selloff that didn’t really materialize, he notes 2021 was “unusual” with stock inflows not seen in 20 to 50 years, depending on whom you ask, that kept markets propped up. So the biggest and strongest companies kept rising and the rest went sideways.\nFor 2022, he sees those highflying stocks falling hard and possibly panicking inexperienced investors. That is because “anybody who’s 30 years old or younger, the last time we had a bear market, they were in high school or even earlier grades so they don’t even have the experience of knowing what it’s like to invest in a bear market,” Kaplan said.\nAmong the warning signs, he highlights a favorite indicator of his — selling and buying by company insiders, which he tracks via J3 Information Services Group.\n“We’ve had all-time record levels of insider selling meaning that the top executives, the people that are the most experienced investors in the world, have been pretty much spending all year getting rid of their stakes in some cases and unloading huge amounts of shares they have accumulated for decades,” said Kaplan.\nFor example, the chairman of broker Charles Schwab who has been selling all year — the stock is up 50% — and of course Tesla CEO Elon Musk has dumped over $8.8 billion — shares are still up 54%. Billions have been sold by the heads of Apple,Facebook parent Meta and Amazon this year.\n“So I think that the people that have the most knowledge are the most worried about a drop and people that have the least experience in some cases, maybe just started trading in the past year or so, consistently, are the most aggressive and the most optimistic about what’s going to happen,” Kaplan said.\n“History has shown us that when you have that big a difference in opinion from the most experienced to the least experienced people that the most experienced ones always come out on top,” he said, adding that the opposite has also held true with big insiders buying at crucial moments, such as in March 2009.\nOne sign that those investors are trying to position more conservatively could be driving dollar gains this year, he added.\nAs for what it will take to normalize price earnings ratios that are on average about “triple where they need to be,” Kaplan said most stocks would need to drop two-thirds. But “when things are either above or below fair value, and they come back to fair value, they rarely stay at fair value. They normally keep going because when people start to see things dropping a lot, they start to panic,” he said.\nFor where to park some cash for the coming storm, Kaplan suggests investors look at I-Bond or Series I savings bonds that can be bought directly from the government and are currently offering a return of 7%.\n“You can put up to $65,000 a year into those and for 30 years, you can just keep them in there and just let them keep collecting whatever interest that they pay, which keeps changing every six months,” he said.\n\nStock futures are pointing to a rebound from Tuesday’s selling. The Hang Seng,meanwhile, dropped 1.4% led by tech stocks. The Turkish lira is diving further after the country’s central bank cut interest rates 100 basis points as widely expected.","news_type":1},"isVote":1,"tweetType":1,"viewCount":190,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":845659700,"gmtCreate":1636336045691,"gmtModify":1636336045789,"author":{"id":"3580791049174344","authorId":"3580791049174344","name":"windz123","avatar":"https://static.tigerbbs.com/3f5527e97f3d63e3fa0d4f05b7f5230c","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"ok","listText":"ok","text":"ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/845659700","repostId":"2181284457","repostType":4,"isVote":1,"tweetType":1,"viewCount":319,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":876486944,"gmtCreate":1637339698991,"gmtModify":1637339699112,"author":{"id":"3580791049174344","authorId":"3580791049174344","name":"windz123","avatar":"https://static.tigerbbs.com/3f5527e97f3d63e3fa0d4f05b7f5230c","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"ok","listText":"ok","text":"ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/876486944","repostId":"1197931355","repostType":4,"isVote":1,"tweetType":1,"viewCount":452,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":847959913,"gmtCreate":1636474120737,"gmtModify":1636474144878,"author":{"id":"3580791049174344","authorId":"3580791049174344","name":"windz123","avatar":"https://static.tigerbbs.com/3f5527e97f3d63e3fa0d4f05b7f5230c","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"ok","listText":"ok","text":"ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/847959913","repostId":"1127189501","repostType":4,"repost":{"id":"1127189501","pubTimestamp":1636470995,"share":"https://www.laohu8.com/m/news/1127189501?lang=&edition=full","pubTime":"2021-11-09 23:16","market":"us","language":"en","title":"Kimbal Musk cashed out $109 million of Tesla stock just before Elon's tweets whacked the share price","url":"https://stock-news.laohu8.com/highlight/detail?id=1127189501","media":"businessinsider","summary":"Tesla board member Kimbal Musk sold around $109 million of the electric-car maker's stock shortly be","content":"<p>Tesla&nbsp;board member Kimbal Musk sold around $109 million of the electric-car maker's stock shortly before his brother Elon knocked the share price by asking Twitter if he should sell a big chunk of his holdings.</p>\n<p>Kimbal, an entrepreneur who sits on Tesla's board of directors, made a number of transactions on Friday according to a Securities and Exchange Commission&nbsp;filing.</p>\n<p>He exercised his stock options to buy 25,000 shares at just $74.17 a pop. Kimbal then sold 88,500 shares in a number of tranches at an average price of around $1,230, making him roughly $108.9 million.</p>\n<p>Elon's younger brother also donated 25,000 shares - which closed at $1,222.09 on Friday - to charity.</p>\n<p>Kimbal has not been the only director to take advantage of the Tesla's blistering rally, which has seen the stock price rise around 1,600% over the last two years.</p>\n<p>Filings&nbsp;from the end of October showed that directors Ira Ehrenpreis, Robyn Denholm and Antonio Gracias sold shares worth hundreds of millions of dollars.</p>\n<p>Tesla&nbsp;shares&nbsp;once&nbsp;fell&nbsp;nearly&nbsp;10%&nbsp;in&nbsp;morning&nbsp;trading.</p>","source":"lsy1636471102575","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Kimbal Musk cashed out $109 million of Tesla stock just before Elon's tweets whacked the share price</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKimbal Musk cashed out $109 million of Tesla stock just before Elon's tweets whacked the share price\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-09 23:16 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://markets.businessinsider.com/news/stocks/kimbal-musk-elon-tesla-stock-share-sale-twitter-poll-2021-11><strong>businessinsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Tesla board member Kimbal Musk sold around $109 million of the electric-car maker's stock shortly before his brother Elon knocked the share price by asking Twitter if he should sell a big chunk of his...</p>\n\n<a href=\"https://markets.businessinsider.com/news/stocks/kimbal-musk-elon-tesla-stock-share-sale-twitter-poll-2021-11\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TSLA":"特斯拉"},"source_url":"https://markets.businessinsider.com/news/stocks/kimbal-musk-elon-tesla-stock-share-sale-twitter-poll-2021-11","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1127189501","content_text":"Tesla board member Kimbal Musk sold around $109 million of the electric-car maker's stock shortly before his brother Elon knocked the share price by asking Twitter if he should sell a big chunk of his holdings.\nKimbal, an entrepreneur who sits on Tesla's board of directors, made a number of transactions on Friday according to a Securities and Exchange Commission filing.\nHe exercised his stock options to buy 25,000 shares at just $74.17 a pop. Kimbal then sold 88,500 shares in a number of tranches at an average price of around $1,230, making him roughly $108.9 million.\nElon's younger brother also donated 25,000 shares - which closed at $1,222.09 on Friday - to charity.\nKimbal has not been the only director to take advantage of the Tesla's blistering rally, which has seen the stock price rise around 1,600% over the last two years.\nFilings from the end of October showed that directors Ira Ehrenpreis, Robyn Denholm and Antonio Gracias sold shares worth hundreds of millions of dollars.\nTesla shares once fell nearly 10% in morning trading.","news_type":1},"isVote":1,"tweetType":1,"viewCount":132,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691237716,"gmtCreate":1640193800525,"gmtModify":1640193800625,"author":{"id":"3580791049174344","authorId":"3580791049174344","name":"windz123","avatar":"https://static.tigerbbs.com/3f5527e97f3d63e3fa0d4f05b7f5230c","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":".","listText":".","text":".","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/691237716","repostId":"1104039472","repostType":4,"repost":{"id":"1104039472","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1640184691,"share":"https://www.laohu8.com/m/news/1104039472?lang=&edition=full","pubTime":"2021-12-22 22:51","market":"us","language":"en","title":"Biogen shares fell 1.2% in early trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1104039472","media":"Tiger Newspress","summary":"Biogen shares fell 1.2% in early trading.A Japanese health ministry panel said on Wednesday that inc","content":"<p>Biogen&nbsp;shares&nbsp;fell&nbsp;1.2%&nbsp;in&nbsp;early&nbsp;trading.<img src=\"https://static.tigerbbs.com/22ab29bf4110d582a44955c778f3cf48\" tg-width=\"713\" tg-height=\"596\" width=\"100%\" height=\"auto\">A Japanese health ministry panel said on Wednesday that inconsistent trial results made it difficult to determine the efficacy of an Alzheimer's treatment developed by Eisai Co and Biogen Inc.</p>\n<p>Tokyo-based Eisai and its United States partner filed for Japanese regulatory approval just over a year ago for the drug Aduhelm, which was approved in the United States in June.</p>\n<p>In a statement the panel cited inconsistent results from global Phase III trials and a lack of clinical significance in the drug's ability to reduce plaques in the brain. The panel said it would take another look if further data is submitted.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biogen shares fell 1.2% in early trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiogen shares fell 1.2% in early trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-22 22:51</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Biogen&nbsp;shares&nbsp;fell&nbsp;1.2%&nbsp;in&nbsp;early&nbsp;trading.<img src=\"https://static.tigerbbs.com/22ab29bf4110d582a44955c778f3cf48\" tg-width=\"713\" tg-height=\"596\" width=\"100%\" height=\"auto\">A Japanese health ministry panel said on Wednesday that inconsistent trial results made it difficult to determine the efficacy of an Alzheimer's treatment developed by Eisai Co and Biogen Inc.</p>\n<p>Tokyo-based Eisai and its United States partner filed for Japanese regulatory approval just over a year ago for the drug Aduhelm, which was approved in the United States in June.</p>\n<p>In a statement the panel cited inconsistent results from global Phase III trials and a lack of clinical significance in the drug's ability to reduce plaques in the brain. The panel said it would take another look if further data is submitted.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BIIB":"渤健公司"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1104039472","content_text":"Biogen shares fell 1.2% in early trading.A Japanese health ministry panel said on Wednesday that inconsistent trial results made it difficult to determine the efficacy of an Alzheimer's treatment developed by Eisai Co and Biogen Inc.\nTokyo-based Eisai and its United States partner filed for Japanese regulatory approval just over a year ago for the drug Aduhelm, which was approved in the United States in June.\nIn a statement the panel cited inconsistent results from global Phase III trials and a lack of clinical significance in the drug's ability to reduce plaques in the brain. The panel said it would take another look if further data is submitted.","news_type":1},"isVote":1,"tweetType":1,"viewCount":379,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691237334,"gmtCreate":1640193698047,"gmtModify":1640193698145,"author":{"id":"3580791049174344","authorId":"3580791049174344","name":"windz123","avatar":"https://static.tigerbbs.com/3f5527e97f3d63e3fa0d4f05b7f5230c","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"ok","listText":"ok","text":"ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/691237334","repostId":"1101599012","repostType":4,"isVote":1,"tweetType":1,"viewCount":506,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691234475,"gmtCreate":1640193526397,"gmtModify":1640193526509,"author":{"id":"3580791049174344","authorId":"3580791049174344","name":"windz123","avatar":"https://static.tigerbbs.com/3f5527e97f3d63e3fa0d4f05b7f5230c","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"ok","listText":"ok","text":"ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/691234475","repostId":"1122126959","repostType":4,"isVote":1,"tweetType":1,"viewCount":716,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":825404306,"gmtCreate":1634253878720,"gmtModify":1634274402538,"author":{"id":"3580791049174344","authorId":"3580791049174344","name":"windz123","avatar":"https://static.tigerbbs.com/3f5527e97f3d63e3fa0d4f05b7f5230c","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"ok","listText":"ok","text":"ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/825404306","repostId":"1119722017","repostType":4,"isVote":1,"tweetType":1,"viewCount":185,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691210367,"gmtCreate":1640193824058,"gmtModify":1640193824123,"author":{"id":"3580791049174344","authorId":"3580791049174344","name":"windz123","avatar":"https://static.tigerbbs.com/3f5527e97f3d63e3fa0d4f05b7f5230c","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"ok","listText":"ok","text":"ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/691210367","repostId":"2193019234","repostType":4,"repost":{"id":"2193019234","pubTimestamp":1640181878,"share":"https://www.laohu8.com/m/news/2193019234?lang=&edition=full","pubTime":"2021-12-22 22:04","market":"us","language":"en","title":"France cancels order for Merck's COVID-19 antiviral drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2193019234","media":"Reuters","summary":"PARIS, Dec 22 (Reuters) - France has cancelled its order for Merck & Co's COVID-19 antiviral drug fo","content":"<p>PARIS, Dec 22 (Reuters) - France has cancelled its order for Merck &amp; Co's COVID-19 antiviral drug following disappointing trial data and hopes instead to receive Pfizer's competing drug before the end of January, the health minister said on Wednesday.</p>\n<p>France is the first country to publicly say it has cancelled an order for the Merck treatment after the company released data in late November suggesting its drug was markedly less effective than previously thought, reducing hospitalisations and deaths in its clinical trial of high-risk individuals by about 30%.</p>\n<p>\"The latest studies weren't good,\" Olivier Veran told BFM TV.</p>\n<p>Merck did not immediately respond to Reuters' request for comment.</p>\n<p>While vaccines are the main weapons against COVID-19 for governments, there are hopes Merck and Pfizer's experimental pills could be a game-changer in reducing the chances of dying or hospitalisation for those most at risk of severe illness.</p>\n<p>France had placed an early order for 50,000 doses of the drug molnupiravir developed by Merck and Ridgeback Biotherapeutics.</p>\n<p>The cancellation would not incur a cost, Veran said.</p>\n<p>In Italy, the office of the special commissioner for the COVID emergency said on Nov 18 it had received a mandate from the health ministry to buy 50,000 courses of Merck's pill and another 50,000 of Pfizer's <a href=\"https://laohu8.com/S/AONE.U\">one</a>. \"The contract has not yet been finalised, but is in progress,\" a spokesperson for the commissioner told Reuters on Tuesday.</p>\n<p>Italian drug regulator Aifa's head Nicola Magrini told a Senate committee on Dec. 9 the two treatments could be available in Italy from the end of January.</p>\n<p>However, regardless of the availability of the drugs, there will be assessments of their use, two top government scientific advisers told Reuters.</p>\n<p>\"There must and will be an evaluation, independently of the assessments of regulatory bodies,\" Walter Ricciardi, top adviser of health minister Roberto Speranza, told Reuters.</p>\n<p>Germany has already bought Merck's antiviral treatment, health minister Karl Lauterbach told Reuters on Wednesday.</p>\n<p>\"This is a binding order,\" he said, adding Berlin was also in talks with Pfizer about buying its antiviral drug.</p>\n<p>The European Medicines Agency is expected to decide whether to approve the Merck and Pfizer pills in the new year.</p>\n<p>Pfizer's Paxlovid has shown near 90% efficacy in preventing COVID-19 hospitalisations and deaths in high-risk patients.</p>\n<p>France had purchased that drug instead, Veran said, without saying how many doses it had secured.</p>\n<p>\"France is lined up to get it before the end of January,\" Veran continued. It has not yet been decided whether the drug would be available over the counter in pharmacies, the minister said.</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>France cancels order for Merck's COVID-19 antiviral drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFrance cancels order for Merck's COVID-19 antiviral drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-22 22:04 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/1-france-cancels-order-mercks-135238223.html><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>PARIS, Dec 22 (Reuters) - France has cancelled its order for Merck & Co's COVID-19 antiviral drug following disappointing trial data and hopes instead to receive Pfizer's competing drug before the end...</p>\n\n<a href=\"https://finance.yahoo.com/news/1-france-cancels-order-mercks-135238223.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4568":"美国抗疫概念","BK4516":"特朗普概念","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4550":"红杉资本持仓","BK4007":"制药","PFE":"辉瑞","MRK":"默沙东","BK4534":"瑞士信贷持仓","BK4559":"巴菲特持仓"},"source_url":"https://finance.yahoo.com/news/1-france-cancels-order-mercks-135238223.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2193019234","content_text":"PARIS, Dec 22 (Reuters) - France has cancelled its order for Merck & Co's COVID-19 antiviral drug following disappointing trial data and hopes instead to receive Pfizer's competing drug before the end of January, the health minister said on Wednesday.\nFrance is the first country to publicly say it has cancelled an order for the Merck treatment after the company released data in late November suggesting its drug was markedly less effective than previously thought, reducing hospitalisations and deaths in its clinical trial of high-risk individuals by about 30%.\n\"The latest studies weren't good,\" Olivier Veran told BFM TV.\nMerck did not immediately respond to Reuters' request for comment.\nWhile vaccines are the main weapons against COVID-19 for governments, there are hopes Merck and Pfizer's experimental pills could be a game-changer in reducing the chances of dying or hospitalisation for those most at risk of severe illness.\nFrance had placed an early order for 50,000 doses of the drug molnupiravir developed by Merck and Ridgeback Biotherapeutics.\nThe cancellation would not incur a cost, Veran said.\nIn Italy, the office of the special commissioner for the COVID emergency said on Nov 18 it had received a mandate from the health ministry to buy 50,000 courses of Merck's pill and another 50,000 of Pfizer's one. \"The contract has not yet been finalised, but is in progress,\" a spokesperson for the commissioner told Reuters on Tuesday.\nItalian drug regulator Aifa's head Nicola Magrini told a Senate committee on Dec. 9 the two treatments could be available in Italy from the end of January.\nHowever, regardless of the availability of the drugs, there will be assessments of their use, two top government scientific advisers told Reuters.\n\"There must and will be an evaluation, independently of the assessments of regulatory bodies,\" Walter Ricciardi, top adviser of health minister Roberto Speranza, told Reuters.\nGermany has already bought Merck's antiviral treatment, health minister Karl Lauterbach told Reuters on Wednesday.\n\"This is a binding order,\" he said, adding Berlin was also in talks with Pfizer about buying its antiviral drug.\nThe European Medicines Agency is expected to decide whether to approve the Merck and Pfizer pills in the new year.\nPfizer's Paxlovid has shown near 90% efficacy in preventing COVID-19 hospitalisations and deaths in high-risk patients.\nFrance had purchased that drug instead, Veran said, without saying how many doses it had secured.\n\"France is lined up to get it before the end of January,\" Veran continued. It has not yet been decided whether the drug would be available over the counter in pharmacies, the minister said.","news_type":1},"isVote":1,"tweetType":1,"viewCount":597,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691210098,"gmtCreate":1640193809019,"gmtModify":1640193809090,"author":{"id":"3580791049174344","authorId":"3580791049174344","name":"windz123","avatar":"https://static.tigerbbs.com/3f5527e97f3d63e3fa0d4f05b7f5230c","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"m","listText":"m","text":"m","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/691210098","repostId":"1118823516","repostType":4,"repost":{"id":"1118823516","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1640183281,"share":"https://www.laohu8.com/m/news/1118823516?lang=&edition=full","pubTime":"2021-12-22 22:28","market":"us","language":"en","title":" Skillsoft To Acquire Codecademy For $525M","url":"https://stock-news.laohu8.com/highlight/detail?id=1118823516","media":"Benzinga","summary":"Skillsoft Corp has agreed to acquire Codecademy, an online learning platform for technical skills, f","content":"<p><b>Skillsoft Corp</b>&nbsp;has&nbsp;agreed to acquire&nbsp;Codecademy, an online learning platform for technical skills, for about $525 million in cash and stock.</p>\n<ul>\n <li>The consideration for the transaction is approximately 40% cash and 60% equity.</li>\n <li>Codecademy, founded in 2011, is based in New York. It has40 million registered learners worldwide and offers learning in 14 programming languages across multiple domains such as application development, data science, cloud, and cybersecurity.</li>\n <li>Codecademy is expected to report $47 million in bookings and $42 million in revenue for the calendar year ended December 31, 2021.</li>\n <li>Skillsoft expects the Codecademy deal to be accretive to gross margin immediately upon closing, which is expected to occur in the first half of 2022.</li>\n <li>Codecademy's team, led by founder Zach Sims, will join Skillsoft with a focus on accelerating growth in Technology &amp; Developer Business</li>\n <li>Skillsoft has secured committed financing from Barclays and Citigroup in connection with the transaction. It held&nbsp;cash and equivalents&nbsp;of $83.4 million as of October 31, 2021.</li>\n <li><b>Outlook</b>: Skillsoft reiterated its FY22 view provided on December 14, 2021, with bookings of $700 million - $720 million; adjusted revenue of $685 million - $700 million; and adjusted EBITDA of $165 million.</li>\n <li><b>Price Action:</b>&nbsp;SKIL shares closed lower by 0.10% at $9.71 on Tuesday.</li>\n</ul>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title> Skillsoft To Acquire Codecademy For $525M</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n Skillsoft To Acquire Codecademy For $525M\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-12-22 22:28</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>Skillsoft Corp</b>&nbsp;has&nbsp;agreed to acquire&nbsp;Codecademy, an online learning platform for technical skills, for about $525 million in cash and stock.</p>\n<ul>\n <li>The consideration for the transaction is approximately 40% cash and 60% equity.</li>\n <li>Codecademy, founded in 2011, is based in New York. It has40 million registered learners worldwide and offers learning in 14 programming languages across multiple domains such as application development, data science, cloud, and cybersecurity.</li>\n <li>Codecademy is expected to report $47 million in bookings and $42 million in revenue for the calendar year ended December 31, 2021.</li>\n <li>Skillsoft expects the Codecademy deal to be accretive to gross margin immediately upon closing, which is expected to occur in the first half of 2022.</li>\n <li>Codecademy's team, led by founder Zach Sims, will join Skillsoft with a focus on accelerating growth in Technology &amp; Developer Business</li>\n <li>Skillsoft has secured committed financing from Barclays and Citigroup in connection with the transaction. It held&nbsp;cash and equivalents&nbsp;of $83.4 million as of October 31, 2021.</li>\n <li><b>Outlook</b>: Skillsoft reiterated its FY22 view provided on December 14, 2021, with bookings of $700 million - $720 million; adjusted revenue of $685 million - $700 million; and adjusted EBITDA of $165 million.</li>\n <li><b>Price Action:</b>&nbsp;SKIL shares closed lower by 0.10% at $9.71 on Tuesday.</li>\n</ul>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SKIL":"Skillsoft Corp."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1118823516","content_text":"Skillsoft Corp has agreed to acquire Codecademy, an online learning platform for technical skills, for about $525 million in cash and stock.\n\nThe consideration for the transaction is approximately 40% cash and 60% equity.\nCodecademy, founded in 2011, is based in New York. It has40 million registered learners worldwide and offers learning in 14 programming languages across multiple domains such as application development, data science, cloud, and cybersecurity.\nCodecademy is expected to report $47 million in bookings and $42 million in revenue for the calendar year ended December 31, 2021.\nSkillsoft expects the Codecademy deal to be accretive to gross margin immediately upon closing, which is expected to occur in the first half of 2022.\nCodecademy's team, led by founder Zach Sims, will join Skillsoft with a focus on accelerating growth in Technology & Developer Business\nSkillsoft has secured committed financing from Barclays and Citigroup in connection with the transaction. It held cash and equivalents of $83.4 million as of October 31, 2021.\nOutlook: Skillsoft reiterated its FY22 view provided on December 14, 2021, with bookings of $700 million - $720 million; adjusted revenue of $685 million - $700 million; and adjusted EBITDA of $165 million.\nPrice Action: SKIL shares closed lower by 0.10% at $9.71 on Tuesday.","news_type":1},"isVote":1,"tweetType":1,"viewCount":409,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691237022,"gmtCreate":1640193637456,"gmtModify":1640193637522,"author":{"id":"3580791049174344","authorId":"3580791049174344","name":"windz123","avatar":"https://static.tigerbbs.com/3f5527e97f3d63e3fa0d4f05b7f5230c","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"ok","listText":"ok","text":"ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/691237022","repostId":"1118823516","repostType":4,"isVote":1,"tweetType":1,"viewCount":358,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691234756,"gmtCreate":1640193600570,"gmtModify":1640193600641,"author":{"id":"3580791049174344","authorId":"3580791049174344","name":"windz123","avatar":"https://static.tigerbbs.com/3f5527e97f3d63e3fa0d4f05b7f5230c","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"ok","listText":"ok","text":"ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/691234756","repostId":"2193927561","repostType":4,"isVote":1,"tweetType":1,"viewCount":448,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":699550744,"gmtCreate":1639846437194,"gmtModify":1639846437302,"author":{"id":"3580791049174344","authorId":"3580791049174344","name":"windz123","avatar":"https://static.tigerbbs.com/3f5527e97f3d63e3fa0d4f05b7f5230c","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"dkejeueu","listText":"dkejeueu","text":"dkejeueu","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/699550744","isVote":1,"tweetType":1,"viewCount":548,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":849619135,"gmtCreate":1635750464650,"gmtModify":1635750464650,"author":{"id":"3580791049174344","authorId":"3580791049174344","name":"windz123","avatar":"https://static.tigerbbs.com/3f5527e97f3d63e3fa0d4f05b7f5230c","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/849619135","repostId":"850756569","repostType":1,"repost":{"id":850756569,"gmtCreate":1634631211448,"gmtModify":1635853120757,"author":{"id":"36984908995200","authorId":"36984908995200","name":"小虎活动","avatar":"https://static.tigerbbs.com/4f487d6799e86204e80dfde72e6040c0","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"title":"[Halloween Game] Trade or Treat!","htmlText":"Hello, dear Tigers!&nbsp; Happy&nbsp;Halloween!&nbsp;🎃🎃🎃&nbsp;&nbsp; <a href=\"https://www.tigerbrokers.com.sg/activity/market/2021/halloween/?lang=en_US#/\" target=\"_blank\">Tap&nbsp;here&nbsp;to&nbsp;play the Halloween game,&nbsp;and&nbsp;you&nbsp;stand&nbsp;a&nbsp;chance&nbsp;to win various rewards!&nbsp;</a> Promotion Period: October 27, 2021 18:00 - November 9, 2021 18:00 (SGT) 1.&nbsp;How to Participate? All Tiger clients may collect points which can be used to redeem rewards by taking part in the Trade or Treating Game. All existing Tiger clients will have 2 game attempts. Clients can get more game attempts by completing different tasks, such as 'Invite a friend' or 'Share Halloween Game'.&nbsp; 2.&nbsp;How to collect points? Each player has 30 seconds to catch falling candies while av","listText":"Hello, dear Tigers!&nbsp; Happy&nbsp;Halloween!&nbsp;🎃🎃🎃&nbsp;&nbsp; <a href=\"https://www.tigerbrokers.com.sg/activity/market/2021/halloween/?lang=en_US#/\" target=\"_blank\">Tap&nbsp;here&nbsp;to&nbsp;play the Halloween game,&nbsp;and&nbsp;you&nbsp;stand&nbsp;a&nbsp;chance&nbsp;to win various rewards!&nbsp;</a> Promotion Period: October 27, 2021 18:00 - November 9, 2021 18:00 (SGT) 1.&nbsp;How to Participate? All Tiger clients may collect points which can be used to redeem rewards by taking part in the Trade or Treating Game. All existing Tiger clients will have 2 game attempts. Clients can get more game attempts by completing different tasks, such as 'Invite a friend' or 'Share Halloween Game'.&nbsp; 2.&nbsp;How to collect points? Each player has 30 seconds to catch falling candies while av","text":"Hello, dear Tigers! Happy Halloween! 🎃🎃🎃 Tap here to play the Halloween game, and you stand a chance to win various rewards! Promotion Period: October 27, 2021 18:00 - November 9, 2021 18:00 (SGT) 1. How to Participate? All Tiger clients may collect points which can be used to redeem rewards by taking part in the Trade or Treating Game. All existing Tiger clients will have 2 game attempts. Clients can get more game attempts by completing different tasks, such as 'Invite a friend' or 'Share Halloween Game'. 2. How to collect points? Each player has 30 seconds to catch falling candies while av","images":[],"top":1,"highlighted":2,"essential":1,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/850756569","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":123,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":857937455,"gmtCreate":1635501516449,"gmtModify":1635501725504,"author":{"id":"3580791049174344","authorId":"3580791049174344","name":"windz123","avatar":"https://static.tigerbbs.com/3f5527e97f3d63e3fa0d4f05b7f5230c","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/857937455","repostId":"850756569","repostType":1,"repost":{"id":850756569,"gmtCreate":1634631211448,"gmtModify":1635853120757,"author":{"id":"36984908995200","authorId":"36984908995200","name":"小虎活动","avatar":"https://static.tigerbbs.com/4f487d6799e86204e80dfde72e6040c0","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"title":"[Halloween Game] Trade or Treat!","htmlText":"Hello, dear Tigers!&nbsp; Happy&nbsp;Halloween!&nbsp;🎃🎃🎃&nbsp;&nbsp; <a href=\"https://www.tigerbrokers.com.sg/activity/market/2021/halloween/?lang=en_US#/\" target=\"_blank\">Tap&nbsp;here&nbsp;to&nbsp;play the Halloween game,&nbsp;and&nbsp;you&nbsp;stand&nbsp;a&nbsp;chance&nbsp;to win various rewards!&nbsp;</a> Promotion Period: October 27, 2021 18:00 - November 9, 2021 18:00 (SGT) 1.&nbsp;How to Participate? All Tiger clients may collect points which can be used to redeem rewards by taking part in the Trade or Treating Game. All existing Tiger clients will have 2 game attempts. Clients can get more game attempts by completing different tasks, such as 'Invite a friend' or 'Share Halloween Game'.&nbsp; 2.&nbsp;How to collect points? Each player has 30 seconds to catch falling candies while av","listText":"Hello, dear Tigers!&nbsp; Happy&nbsp;Halloween!&nbsp;🎃🎃🎃&nbsp;&nbsp; <a href=\"https://www.tigerbrokers.com.sg/activity/market/2021/halloween/?lang=en_US#/\" target=\"_blank\">Tap&nbsp;here&nbsp;to&nbsp;play the Halloween game,&nbsp;and&nbsp;you&nbsp;stand&nbsp;a&nbsp;chance&nbsp;to win various rewards!&nbsp;</a> Promotion Period: October 27, 2021 18:00 - November 9, 2021 18:00 (SGT) 1.&nbsp;How to Participate? All Tiger clients may collect points which can be used to redeem rewards by taking part in the Trade or Treating Game. All existing Tiger clients will have 2 game attempts. Clients can get more game attempts by completing different tasks, such as 'Invite a friend' or 'Share Halloween Game'.&nbsp; 2.&nbsp;How to collect points? Each player has 30 seconds to catch falling candies while av","text":"Hello, dear Tigers! Happy Halloween! 🎃🎃🎃 Tap here to play the Halloween game, and you stand a chance to win various rewards! Promotion Period: October 27, 2021 18:00 - November 9, 2021 18:00 (SGT) 1. How to Participate? All Tiger clients may collect points which can be used to redeem rewards by taking part in the Trade or Treating Game. All existing Tiger clients will have 2 game attempts. Clients can get more game attempts by completing different tasks, such as 'Invite a friend' or 'Share Halloween Game'. 2. How to collect points? Each player has 30 seconds to catch falling candies while av","images":[],"top":1,"highlighted":2,"essential":1,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/850756569","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":254,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}